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Resumo 
 
 
A biocatálise, e em particular a evolução dirigida de enzimas e posterior 
expressão em bactérias, permitiu aos químicos obter moléculas complexas com 
elevada estéreo- e regiosseletividade e baixo impacto ambiental. A Monoamina 
oxidase de Aspergillus niger (MAO-N) é uma oxidase, dependente de FAD e 
oxigénio, que catalisa a desaminação de aminas primárias. No Manchester 
Institute of Biotechnology foram efetuadas rondas sucessivas de evolução 
dirigida desta enzima, que permitiram a oxidação e resolução de aminas 
secundárias e terciárias. Contudo, não se encontra descrita na literatura a 
oxidação de compostos dimetoxilados com MAO-N. 
O uso de tetra-hidroisoquinolinas (THIQs) quirais na indústria farmacêutica é 
cada vez mais comum devido às suas importantes propriedades 
antimicrobianas, antibióticas, anti tumorais ou antimuscarínicas. Assim, é cada 
vez mais necessário o desenvolvimento de métodos de síntese assimétrica 
destes compostos. 
Neste trabalho procurámos funcionalizar THIQs através de métodos 
biocatalíticos. Para tal, estudámos a atividade várias variantes da MAO-N com 
derivados da THIQ. Os dados obtidos foram usados para a construção de uma 
nova variante capaz de oxidar a (S)-6,7-dimetoxi-1,2,3,4-tetra-hidroisoquinolina 
com um rendimento de 60%. Foi também efetuada a resolução de várias THIQs 
com as variantes de MAO-N disponíveis.  
Por fim, neste trabalho foi desenvolvida uma cascata enzimática com três passos 
sem purificação intermédia para a síntese de ácidos 1,2,3,4-tetra- 
-hidroisoquinolina-1-carboxílicos. Foram obtidas 1-cianotetra-hidroisoquinolinas 
com rendimentos superiores a 50% e o ácido tetra-hidroisoquinolina-1- 
-carboxílico com um rendimento de 13% (e.e. 88%). 
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Abstract 
 
Biocatalysis, and particularly the directed evolution of enzymes and further 
expression in bacterium, has allowed chemists to obtain complex molecules with 
improved stereo and regio-selectivity, at high reaction rates and with a low 
environmental impact. Monoamine oxidase from Aspergillus niger (MAO-N) is a 
FAD and oxygen dependent oxidase that catalyses the deamination of primary 
amines. Successive rounds of directed evolution at the Manchester Institute of 
Biotechnology have allowed the oxidation and deracemisation of secondary and 
tertiary amines with MAO-N variants. Nevertheless, significant activity of these 
mutants with dimethoxylated substrates is yet to be reported. 
Chiral tetrahydroisoquinoline (THIQ) derivatives are increasingly common in the 
pharmaceutical industry due to their antimicrobial, antibiotic, antitumor or 
antimuscarinic properties, demanding for easy and highly selective methods for 
their synthesis. 
In this work, we used biocatalytic methods to functionalize THIQs. First, we 
studied the substrate scope of MAO-N variants with several THIQs, and used the 
data obtained to construct a new mutant capable of oxidizing 
(S)-6,7-dimethoxy-1-methyltetrahydroisoquinoline with approximately 60% yield. 
Moreover, the deracemisation of several THIQs with MAO-N variants was 
performed with success.  
Finally, a one pot three step cascade using two distinct enzymes was developed 
for the selective synthesis of tetrahydroisoquinoline-1-carboxylic acids from 
simple tetrahydroisoquinolines, at low temperatures and in water.  
1-Cyanotetrahydroisoquinolines were obtained with good yields (>50%), and 
tetrahydroisoquinoline-1-carboxylic acid was obtained with 13% yield and 88% 
e.e.. 
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1.1 α-CHIRAL AMINES AND THEIR IMPORTANCE IN THE CHEMICAL 
INDUSTRY 
1.1.1 Overview 
Since the discovery of chirality by Louis Pasteur more than a century ago, its importance has 
spread to all areas of industrial and pharmaceutical chemistry.1 In fact, more than half of 
currently marketed drugs present a chiral centre and an increase in these values, driven by 
the rise in drug complexity, is expected.2 These compounds are usually administered in their 
cheaper racemic form, an equimolar mixture of both enantiomers, but history has shown that 
possible health hazards can mandate the use of an enantiopure drug. A common example can 
be found in Contergan®, an over-the-counter drug from the mid-20th century. This medicine 
contained the active ingredient thalidomide as a racemate and was widely advertised for the 
relief of morning-sickness in pregnant women. However, while (R)-thalidomide (2) was an 
effective sedative with great pharmaceutical properties, the (S) enantiomer (1) was 
teratogenic to foetus (Figure 1), causing severe malformations in over 10,000 children.3 An 
additional boost in the search for enhanced enantiopure drugs arose with FDA’s “chiral 
switch” program, fastening the approval procedure for single-enantiomer drugs from 
previously used racemic active principles (APIs).4 
 
Figure 1. Both enantiomers of thalidomide 
Chiral amines, particularly ones with an asymmetric carbon in α-position, represent a 
significant part of chiral drugs, as seen in the examples with relevant pharmacological 
application in Figure 2. Their potential extends to other chemical areas, providing useful 
scaffolds for chiral catalysts5, resolving agents6 and ligands in metal complexes7 for diverse 
applications. 
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Figure 2. Examples of α-chiral amine-based drugs currently marketed 
1.1.2 Synthetic routes to single-enantiomer α-chiral amines 
Various reliable routes for the synthesis of substituted amines have been developed and are 
extensively reported elsewhere.8,9 Similarly, several techniques have been reported in the 
search for their pure chiral analogues, by either chiral synthesis or posterior resolution.10 
Unfortunately, these methods still pose concerns, either by their low versatility, long            
multi-step procedures, low yields or selectivity or high environmental impact. Besides, even 
optimal laboratory procedures may not be adequate for industrial application due to 
complicated separation methods. The most common methods for the synthesis of 
enantiopure chiral amines are concisely explained in the following topics. 
1.1.2.1 Asymmetric synthesis 
Asymmetric synthesis encompasses the creation of a chiral centre from a prochiral 
compound, using either a chiral auxiliary or a chiral catalyst. In the first approach, a 
stoichiometric amount of a suitable compound is introduced and covalently bounds to a 
prochiral molecule to form an asymmetric centre with a particular configuration. Cleavage 
of the auxiliary leads to a pure chiral product. Instead, a chiral catalyst can be used in small 
amounts to increase the selectivity of a reaction involving a stereogenic centre, for example, 
by coordinating with the substrate. In both cases the cost of the chiral compound and its 
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separation process from the reaction product, as well as its recyclability, can be a major 
factor in the scale up of such processes.11 
Several synthetic routes have been developed according to these criteria. The asymmetric 
reduction of imines or enamides, either aliphatic or aromatic, with chiral Lewis bases12, 
metal complexes13 or organocatalysts14 can be considered the preferential route in large-
scale synthesis. Nevertheless, selective amination from aldehydes (reductive amination) or 
alkenes (hydroamination) along with some more complex approaches can also be used.10,15 
An example is found in the 2009 synthesis of sitagliptin (9), the API in the antihyperglycemic 
Januvia® (Scheme 1). The use of a rhodium catalyst for the enantioselective hydrogenation 
of the enamine (8) allowed, at the time, for a new one-pot route with high yield and purity 
(>95% e.e.), combined with a large reduction in waste production.16 
 
Scheme 1. Final step in the industrial synthesis of Sitagliptin by Merck & Co, Inc. 
 
1.1.2.2 Chiral pool synthesis 
“Chiral pool” is a synthetic strategy that uses cheap and easily obtainable enantiopure 
substrates as the starting point in the synthesis of complex chiral compounds, therefore 
eliminating the need for final resolution steps. This approach has some limitations as 
common chiral substrates are limited to some amino acids, hydroxy acids, sugars and other 
alkaloids. Still, techniques have been reported that allow inversion in the configuration of 
the enantiopure substrate, increasing the scope of this strategy.17 An example of a chiral pool 
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approach can be seen in the synthesis of tryptoline derivatives (11) from chiral tryptophan 
derivatives (10) (Scheme 2).18 
 
Scheme 2. Synthesis of tryptolines from chiral tryptophan derivatives. 
1.1.2.3 Crystallization 
Preferential crystallization stands as one of the first routes to obtain enantiopure compounds. 
In consists in the chemical property, first defined by Louis Pasteur, that some racemates tend 
to crystalize in mixtures of enantiopure crystals, that is, an enantiomer has a greater affinity 
to crystalize in a crystal of the same isomer.19 Unfortunately, only a small fraction of racemic 
compounds can be resolved by this technique. A particular downside is that even full 
recovery of the wanted isomer achieves only 50% yield.1 
An alternative technique with limited applicability was also found by Pasteur in 1853.20 
Diastereomer crystallization comprises the separation of an enantiomer by selective 
crystallization of the salt formed with a readily available enantiopure compound, alias, 
resolving agent. Praziquantel (PZQ) (12), to this moment the main API used in the treatment 
of schistosomiasis, is presented as an example. Besides not having any therapeutic effect, 
(S)-PZQ is extremely bitter and therefore undesirable in the formulation. Unfortunately, the 
presence of an amide bond has hindered the development of an asymmetric synthesis. 
Nevertheless, the diasteromeric crystallization of (13) with (-)-dibenzoyl-L-tartaric acid, 
followed by recrystallization, neutralization, extraction with dichloromethane (DCM) and 
acylation, to form (R)-Praziquantel (15) has recently been reported with 33% yield and 97% 
e.e. (Scheme 3). Moreover, the resolving agent could be recycled with 89% yield.21 
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Scheme 3. Diastereomer crystallization for the synthesis of (R)-PZQ 
 
1.1.2.4 Kinetic resolution 
Kinetic resolution explores the different reactivity of the enantiomers in a racemic mixture 
with a given compound, allowing a simple separation of the reacted and unreacted species. 
The final purpose of this technique is the selective full conversion of only one enantiomer, 
allowing a theoretical maximum yield of 50%.22  
A different and more appealing variant to this resolution method is the dynamic kinetic 
resolution (DKR). This approach allows a yield above 50% by assuming that both isomers 
are interchangeable during the reaction, sometimes using a catalyst to drive the process.23 
Recently, a different DKR methodology has been applied where a non-chiral reaction 
product, formed by a selective reaction with one isomer, is converted back to the reagent, 
with a non-selective catalyst, in a racemic manner. After several cycles, it is theoretically 
possible to obtain an enantiopure compound. 
In fact, DKR is experiencing an exponential growth driven by the recent boom in biocatalysis 
and genetic engineering. Enzymes are great catalysts due to their high selectivity, low cost 
and mild reaction conditions but, until now, the need to use reagents close to the enzyme’s 
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natural substrate has hindered further investigation. However, the consistent drop in the price 
of gene sequencing and synthesis and the large investment in the development of this area 
have supported the discovery of a broad range of enzymes and further appearance of several 
engineered enzymes with a wide substrate scope. The advantages and disadvantages of 
enzymatic dynamic kinetic resolution in current organic synthesis, by comparison with its 
chemical counterpart, are briefly presented in Figure 3.23 
 
 
Figure 3. Visual comparison between chemical and enzymatic DKR. 
 
One example of an enzymatic DKR is found in an article by Yasukawa et al., where both 
(R) (17) and (S) (18) enantiomers of simple amino acids could be obtained from their nitrile 
analogue (16) by a cascade reaction with a non-selective nitrile hydratase from Rhodococcus 
opacus and either a D-aminopeptidase from Ochrobactrum anthropic or a L-amino acid 
amidase from Brevundimonas diminuta (Scheme 4). Remarkably, α-amino-ε-caprolactam 
(ACL) racemase from Achromobacter obae was used in the interconversion of both amide 
enantiomers.24 
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Scheme 4. Synthesis of enantiopure amino acids by the DKR of racemic α-amino nitriles. 
1.1.3 Tetrahydroisoquinoline as an important building block in the chemical 
industry 
1.1.3.1 Overview 
The large family of isoquinolines alkaloids is ubiquitous in chemical research, with broad 
occurrence in nature and extensive application in all areas of industrial chemistry. Among 
them, the 1,2,3,4-tetrahydroisoquinoline (THIQ) scaffold (19) (Figure 4) has been 
extensively studied for its natural incidence in plants and humans.25 The interest in these 
particular compounds began with allegations of their relationship with chronical alcoholism 
and role in behavioural disorders. Studies in the expression of THIQ and its relation with 
blood alcohol levels in the brain began as early as 1934, but only in 1970 was any definitive 
evidence presented. It was shown that ethanol is oxidised to acetaldehyde by alcohol 
dehydrogenases in the brain, which then readily reacts with neurotransmitters to form 
THIQ’s such as salsolinol (21) (Figure 5).26 Studies have shown that some THIQs can be 
partially responsible for chronic alcoholism, greatly stimulating alcohol consumption. 
Nevertheless, several theories in the mechanism through which these heterocyclic 
compounds are synthesized remain unopposed.27 
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Figure 4. Structure of THIQ and atom number nomenclature adopted in this work 
Further research has determined that dopamine (20) derived THIQs such as salsolinol (21) 
and norsalsolinol (22) (Figure 5) actively modulate neurotransmission, catecholamine 
biosynthesis and mitochondrial activity28, particularly by its interaction with monoamine 
oxidase (MAO)29. Although no unequivocal proof has been reported, THIQ’s have also been 
greatly associated with Parkinson disease and attention-deficit/hyperactivity disorder 
(ADHD)30. It is reported that research in this area can potentially lead to new treatments 
based on THIQ’s. 
 
Figure 5. Structure of THIQ’s associated with brain disorders. 
1.1.3.2 Current applications 
The presence of a wide range of natural THIQ alkaloids and the previously mentioned 
studies of their impact in the human body lead to the development of derivatives with a wide 
range of biological activities. Indeed, these compounds have shown antidiuretic activity 
through the selective inhibition of M3 muscarinic receptors31, sleep-promoting activity by 
the inhibition of orexin receptors 1 and 232, anti-HIV (human immunodeficiency virus) 
activity by the inhibition of HIV-1 reverse transcriptase33 and high anticancer activity against 
breast cancer cells34. Moreover, some derivatives have proven to be good inhibitors of            
P-glycoproteins, transporter proteins associated to drug resistance and brain diseases such as 
Parkinson and Alzheimer.35  
Three sub-classes of THIQ’s with distinctive structures are presented in Figure 6. First, 
tetrahydroisoquinoline-3-carboxylic acid (TIC) derivatives (23) are constrained analogues 
of phenylalanine and its use in peptide-based drugs36 has shown remarkable potential for the 
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treatment of atherosclerosis, opioid-dependence, hepatitis C, among others. Quinapril 
(Accupril®: Pfizer) is, at the moment, the most important TIC derivative, acting as an 
angiotensin-converting-enzyme (ACE) inhibitor for the treatment of hypertension. Second, 
norcoclaurine (24), a 1-benzyltetrahydroisoquinoline found in high concentration in the 
fruits of Nandina domestica, is used as fat-burner and a mild anti-asthmatic.37 Derivatives 
of this scaffold include morphine and codeine, analgesics, aporphine, an antipsychotic, and 
tubocurarine, a muscle relaxant. Finally, protoberberine alkaloids such as berberine (25) are 
extensively marketed as food supplements for diabetics38 but have shown relevant 
cardiovascular, anti-cancer, anti-depressive and anti-inflammatory activities.39 
 
Figure 6. Examples of THIQ compounds in three major sub-classes with important 
biological activities. 
1.1.4 Asymmetric synthesis of C1 substituted tetrahydroisoquinolines 
To this day numerous methods have been reported for the synthesis of THIQs. In fact, the 
challenge presented in the stereo centre in C1 has also encouraged scientists to develop 
asymmetric routes to these compounds. Three common approaches towards C1 substituted 
THIQ’s - the Pictet-Spengler (A), Bischler-Napieralski (B) and Pomeranz-Fritsch-Bobbitt 
(C) reactions - are presented in this work, as seen in Scheme 5. Nevertheless, today’s 
scientists still struggle with its synthesis, as no method reported is without flaw. 
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Scheme 5. Main routes towards the asymmetric synthesis of 1-substituted THIQ’s. 
The Pictet-Spengler reaction was discovered more than 100 years ago, in 1911, for the 
synthesis of THIQ and it is now one of the most important reactions in the synthesis of 
heterocyclic compounds.40 Over the last 25 years, the remarkable progress in the asymmetric 
form of this synthesis has spurred a new area of investigation. Chemically, it is generally 
performed in aprotic solvents with acid catalysis and comprises the condensation of a 
phenylethylamine derivative (26) with an aldehyde (27) to form an iminium intermediate 
(28). This species is promptly attacked by the aromatic ring’s π system and restores 
aromaticity to form a THIQ (34) (Scheme 5).41 Several catalysts have been explored towards 
this synthesis, including chiral auxiliary groups42, Lewis and Brönsted acids43, 
organocatalysts44, among others. 
Notably, an enzymatic Pictet-Spengler synthesis of THIQs has also been developed through 
the use of norcoclaurine synthase (NCS), responsible in nature for the synthesis of                
(S)-norcoclaurine.45 Although wide applicability of this enzyme for                                                          
1-benzyltetrahydroisoquinolines is still to be reported due to its very limited substrate scope 
(it required a 7-OH aromatic substituent46), a remarkable bioengineering experiment allowed 
the expression of the THIQ alkaloid magnoflorine (39) using a combination of NCS, 
methyltransferases (MTs) and cytochrome P450 (CYP).47 A summary of the metabolic 
pathway can be seen in Scheme 6.  
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Scheme 6. Cascade enzymatic synthesis of magnoflorine from simple and available 
substrates.47  
The Bischler-Napieralski reaction, followed by hydrogenation, can also be used in the 
asymmetric synthesis of THIQ’s. An acylated dopamine derivative (29) reacts with 
appropriate catalyst, usually POCl3, P2O5 or ZnCl2, to form an iminium intermediate that 
promptly cyclizes into a 3,4-dihydroisoquinoline (30). This compound can then be 
asymmetrically reduced by a variety of methods to form the desired THIQ’s (34) (Scheme 
5).48  
Finally, the Bobbitt modification to the Pomeranz and Fritsch synthesis of quinolines allows 
for a rather complex synthesis of THIQ’s. In fact, this route requires two reductions to reach 
the target molecule or a reaction of the imine group prior to the final cyclization-                                 
-hydrogenation step. First, a N-benzyliminoacetaldehyde diethyl acetal compound (33) is 
formed by reaction of the free benzylaldehyde derivatives (31) with (32) (Scheme 5). The 
imine group is either reacted or reduced to its amine analogue and this intermediate is 
reductively cyclized to afford the desired core (34).49 Although not common in THIQ 
synthesis, this method has been successfully applied towards the synthesis of 
protoberberines, for example by Grajewska et al.50, where the presence of the imine 
intermediate proved advantageous as a reactive site for further functionalization.  
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1.2 BIOCATALYSIS: A GREEN PATH IN CHIRAL AMINE SYNTHESIS 
1.2.1 Overview 
The chemical synthesis of enantiopure chiral compounds often requires a compromise 
between yield and enantiomeric purity. Existing industrial procedures usually require 
additional resolution steps, greatly reducing the final yield and increasing the E-factor.51 In 
fact, by 2007, the pharmaceutical industry presented the highest E-factor, ranging from 25 
to 10052, due to rather complex chiral targets. Therefore, it has shown a particular interest in 
the development of cost-effective, sustainable alternatives to these resolution methods.53  
Nowadays, the development of biocatalytic synthetic methods can be highly appealing in 
synthetic chemistry due to the use of cheap, non-toxic and renewable catalysts that can 
achieve extremely high selectivity at mild pH, temperature and pressure conditions and with 
low waste production.54,55 Still, the use of water as a non-toxic solvent can limit the 
concentration of non-polar substrates and demand a final extraction step, leading to higher 
production costs.56 One acclaimed use of enzyme catalysis in industrial amine synthesis is 
the transaminase (TA)/pyridoxal phosphate (PLP) selective reductive amination of a 
diketone sitagliptin intermediate (40) (Scheme 7), substituting the previously mentioned 
chemical method (Scheme 1).57  
 
Scheme 7. TA catalysed amination in the synthesis of sitagliptin 
Biocatalysis can be defined, as said by Bornscheuer et al., as “the application of enzymes 
and microbes in synthetic chemistry, [using] nature’s catalysts for new purposes (…)”.58 Its 
first applications in chemical synthesis consisted in the direct use of cell extracts to convert 
a given substrate into a desired molecule. Since then, it has evolved to increase enzyme 
activity towards unnatural molecules, for example, through the use of evolution and 
heterologous expression techniques. Today’s research in biocatalysis focuses on two main 
challenges: the discovery and engineering of enzymes with broad substrate scope for the 
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production of complex chiral molecules, and the scale-up of these catalytic systems to 
industrial applications, increasing enzyme stability and maximum substrate concentration. 
In the following topic, the various steps required in a full biocatalytic research are described. 
1.2.2 Development of an enzymatic synthesis: main steps 
1.2.2.1 Enzyme discovery 
Enzyme discovery stands as the basis for all biocatalytic development. Traditionally, new 
enzymes were discovered by the culture of environmental samples with media enriched with 
a suitable substrate. However, this process was time consuming and not reliable in the 
discovery of specific enzymes. Moreover, over 99% of all microbes are still unculturable 
today. Fortunately, breakthroughs in deoxyribonucleic acid (DNA) sequencing and 
computer processing power allowed for more methodical alternatives such as 
metagenomics.59 
In metagenomics, the entire DNA of a given environmental sample is extracted and cloned 
into bacterial cloning vectors for later expression. The library of genes ultimately generated 
can then be sequenced and searched for homologous enzymes (Figure 7 - A). Although 
sometimes inaccurate, homology proposes that the similarity in structure presented by 
different enzymes can correspond to similar activities.  
A more thorough approach requires the phenotypic screening of all expressed enzymes from 
the environmental DNA with a substrate of interest (Figure 7 - B), followed by sequencing 
of the most promising results. Several more recent metagenomic approaches can be explored 
in the reference presented.60 
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Figure 7. Metagenomics in gene discovery 
1.2.2.2 Enzyme production: expression and purification 
In the XX century, the development of enzymatic synthesis proceeded at a slow pace, 
hindered by long production and purification procedures. In fact, the isolation of enzymes 
from their native species - animals, plants, fungi or bacteria – for biocatalysis proved to be 
sometimes laborious and inefficient, encouraging scepticism in future industrial 
applications. The discovery of recombinant DNA in 1970 revolutionized this field, allowing 
scientists to express a given enzyme in a different host – heterologous expression. 
Nowadays, recombinant expression is widely used, with most enzymes overexpressed in 
bacterial or fungal hosts. Typical organisms include Escherichia coli and Pichia pastoris 
due to their high expression, easy culture and accessible genetic manipulation. Moreover, 
commercial strains of these organisms have been genetically modified to increase either 
plasmid replication or translation, to reduce the number of endonucleases and to increase 
growth rate. The engineered strain can then be used for either cloning or expression 
purposes.61 
Several factors must be taken into account in the heterologous expression of protein. First, a 
pure sample of the gene of interest must be inserted into a suitable plasmid. A plasmid is a 
DNA molecule with self-replicating abilities, containing an appropriate origin of replication. 
This unit can also contain, among others, a transcription toolbox, markers for antibiotic 
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resistance and one or several genes. Circular plasmids are used in E. coli for extensive 
replication in the cytoplasm while linearized plasmids are used in P. pastoris for insertion in 
the host’s genome.62,63 
The plasmid must then be passively transported through the cell’s membrane to the 
intracellular medium. For that, it requires an increased membrane permeability generated by 
the exposure to harsh physical conditions, in a procedure called transformation. In E. coli a 
sudden rise in temperature in the presence of divalent cations is enough to force plasmid 
DNA to enter the cell through the cell pores (heat shock), while in P. pastoris a more delicate 
procedure is required to avoid cell damage where an electrical current can generate transient 
holes in the cell’s membrane (electroporation).62,63 Finally, the recombinant cell can be 
grown in an appropriate culture and purified with one of the procedures extensively reported 
elsewhere.64 
One additional topic must be addressed for the reader to fully understand the following work. 
Codon bias defines the preference of each organism for specific degenerate codons over 
others, establishing that adverse consequences can arrive from “silent mutations”. According 
to the literature, codon bias can affect protein folding and influence protein expression for a 
factor up to 1000. Several causes have been identified for this phenomenon, including 
differences in tRNA (transfer ribonucleic acid) and codon frequency, in the spacial proximity 
between codons recognized by the same tRNA and in the unfavourable interactions between 
specific consecutive tRNA’s.65 
Two different strategies can provide a quick solution to these problems. First, it is suggested 
that expression in a more complex organism, with a larger genome, can reduce the impact 
of frequency bias. This method can be particularly effective if the new organism has a 
smaller genetic distance to the native one. In alternative, and more effectively, it is now 
possible to codon-optimize a gene for a target organism with carefully designed algorithms 
and create the modified gene by de novo synthesis. Nevertheless, the costs of DNA synthesis 
remain significant for most research groups and must be taken into account. Also, and as 
mentioned before, codon-optimization can be ineffective, as significant changes to the codon 
sequence can alter protein folding and lead to the expression of inactive enzyme.65,66 
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1.2.2.3 Enzyme engineering 
The emergence of enzymes as sustainable catalysts in the transformation of natural 
chemicals has driven research for its application in non-natural compounds as well. Synthetic 
biology has addressed this issue with the development of enzyme engineering. Early 
experiments in mutagenesis were laborious and full mutation of all amino acids in a given 
enzyme, followed by its phenotypic screening, is still not physically possible. To explain, 
even the complete mutation of a 10 amino acid long protein requires the screening of over 
10 trillion sequences. To further difficult enzyme optimization, the misconception of 
additivity - the activity of a double mutated enzyme can be predicted as an improved activity 
of the two single mutants - has been more recently replaced for epistasis, in which the effect 
of a mutation can be affected by the remaining protein sequence. This concept can be 
summarized by the “fitness landscape” presented in Figure 8, where the route towards the 
enzyme with optimum activity can go through several misleading local maximus and even 
mutations that, in that particular step, cause a decrease in activity.67 
 
Figure 8. Simulated fitness landscape in directed evolution. The activity of a given enzyme 
 can be optimized to peak , where a local maximum can be mistaken for the optimal 
activity, or peak , where several misleading disadvantageous mutations are required to 
reach the global activity maximum. Adapted from Shaffe, T..68 
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Directed evolution tries to overcome this difficulty by mimicking natural evolution with a 
twist (Figure 9). For the purpose of this work, it can be defined as the protein engineering 
of enzymes, by iterative rounds of mutagenesis, for a pre-defined purpose. Procedures for 
the identification of the best desired mutants, selection or screening, are quite specific and 
will not be described in this chapter. Nevertheless, the reader is encouraged to explore solid-
-support selection methods and more recent high throughput screening assays.69 Nowadays, 
the procedures involved in generating enzyme variation are the most debatable and three of 
the most generally applied techniques are here summarized.  
Random mutagenesis by error-prone polymerase chain reaction (epPCR) is perhaps the first 
and most basic method in directed evolution (Figure 9 - 2a). It involves the use of altered 
PCR conditions to increase the error rate in DNA replication, generating randomly mutated 
DNA sequences. Although common, this method comprehends several limitations, including 
a high ratio of incomplete or insoluble proteins. In fact, it has been reported that up to 3 in 
every 64 mutations generate a new stop codon, leading only to partial protein expression. 
Furthermore, consecutive mutations and complete libraries cannot be obtained by this 
technique. Nevertheless, random mutation can still be important as a quick method to reveal 
unpredictable mutations that can alter a protein’s secondary structure and significantly 
improve its activity.70 
DNA shuffling was first reported by Stemmer et al. as a technique for the creation of highly 
chimeric gene libraries, formed by the fragmentation of several homologous genes, followed 
by recombination and PCR amplification (Figure 9 - 2b). Unfortunately, it is reported that 
a reduction in variability is usually found due to bias similar to the ones previously 
mentioned in epPCR. This technique has also been used to better assess multiple mutations 
by recombining single mutated gene fragments, obtained by either epPCR or site-directed 
mutagenesis.70,71 
In focus in this particular work is site-directed mutagenesis (SDM), an in vitro method that 
uses PCR with mutagenic primers to introduce specific sequence changes (Figure 9 - 2c). 
This technique is widely used in the creation of gene libraries, designing primers so that a 
mixture of bases is found at a specific location, in a so called degenerate codon. A list with 
the most used degenerate codons, encoding for different sets of amino acids, is referred 
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elsewhere. A large number of samples is usually required to attain all 20 amino acids in a 
given position, limiting the number of mutations viable in a research laboratory.70 
 
 
Figure 9. Example of an enzyme engineering experiment. It is highlighted that iterative 
cycles of this experiment are usually performed to achieve optimal activity. 
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1.2.3 Enzymes employed in chiral amine synthesis 
Several classes of enzymes have been used in the synthesis of chiral amines, through the 
kinetic resolution of racemic substrates or the asymmetric synthesis from ketones, imines or 
α-unsaturated acids. These classes are summed up in Figure 10.  
 
Figure 10. Enzymes used in the synthesis of chiral amines: examples  
Ammonia lyases (AL) (E.C. 4.3.1) are a sub-class of enzymes with narrow substrate scopes 
that catalyse the reversible break of a C-N bond, often forming a double bond in the process 
and releasing ammonia. Remarkably, a methylaspartate ammonia lyase variant has been 
reported that can catalyse the addition to 2-methylfumaric acid of a variety of primary amines 
containing alkyl, benzyl and electron-rich substituents.72 
Nevertheless, the reader is guided towards phenylalanine ammonia lyase (PAL) as a 
promising enzyme for future applications. This enzyme is specific for the deamination or 
synthesis of L-Phe and, to a lesser extent, L-Tyr,73 but directed evolution experiments have 
recently been reported that allow halogen substituents in the aromatic ring.74 Two important 
uses of this lyase, the synthesis of L-Phe (42 a), an aspartame precursor, and 2-halogenated 
phenylalanine75 (43), an indoline precursor (44), are presented in Scheme 8. 
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Scheme 8. PAL in the synthesis of amino acids. 
Amine dehydrogenases (AmDHs) (E.C. 1.4.1) are responsible for the asymmetric reductive 
amination of ketones, using ammonia and generating water as a by-product. These enzymes 
are usually NADH-dependent and require a recycling system such as glucose/glucose 
dehydrogenase (GDH).76 In a similar matter to ALs, AmDHs present very limited substrate 
scopes and have only recently been subjected to directed evolution. Still, a phenylalanine 
dehydrogenase (PheDH) mutant has been successfully used for the amination of 4-phenyl-           
-2-butanone (45) with >95% for conversion and >98% e.e. (Scheme 9).77 
 
Scheme 9. Asymmetric amination of 4-phenyl-2-butanone by a PheDH triple mutant 
Transaminases (E.C. 2.6.1), also called aminotransferases, catalyse the reversible transfer of 
NH2 from an α-amino acid to an α-keto acid, using PLP as an amine carrier.78 They can be 
classified as α-TA and ω-TA, depending on the amine’s position. Unfortunately, the 
application of these enzymes in industrial synthesis is progressing slowly as scientists 
struggle to overcome their severe product inhibition, and, for now, continuous product or 
sub-product extraction remains the overall industrial strategy.79 
ω-TAs have an increased versatility for future applications, accepting aldehydes, ketones or 
acids for the asymmetric synthesis of amines. In fact, these enzymes have been used in the 
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selective monoamination of diketones to form cyclic amine precursors.80,81 Remarkably, an 
enzymatic cascade has been reported for the one-pot synthesis of these heterocycles with a 
carboxylic acid reductase (CAR), a ω-TA and an imine reductase (IRED) (Scheme 10). In 
some cases highly enantiopure disubstituted molecules were readily obtained - (51) and 
(52).82 
 
Scheme 10. One pot CAR-ATA-IRED cascade for the asymmetric synthesis of piperidines 
As seen in the last example, IREDs can also catalyse the asymmetric synthesis of amines by 
the NADPH dependent reduction of imines or iminium ions. Unlike the previous examples, 
these enzymes can access primary, secondary and even tertiary amines starting from either 
ketones or imines. Although advantageous, these enzymes have only been explored for 
biocatalysis in the last five years.83 
An (R)-IRED from Streptomyces sp. was recently reported for its ability to synthesize a wide 
range of cyclic secondary and tertiary amines, from pyrrolidines to azepanes. In Scheme 11, 
the synthesis of 1-methyl and N-methyltetrahydroisoquinolines is presented with conversion 
reaching 98% and great enantiomer excesses.84 
 
Scheme 11. Asymmetric synthesis of tetrahydroisoquinolines with an (R)-IRED 
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Two enzymes have been extensively reported for the deracemisation of chiral amines. 
Lipases can catalyse the enantioselective hydrolysis or synthesis of esters (Esterases - E.C. 
3.1.1) and are currently one of the leading biocatalysts in lipid bio-industry. Moreover, they 
present high stability in organic solvents and an unusually high substrate scope, making them 
ideal for kinetic resolution experiments and future industrial application.85 
Candida antarctica Lipase B (CAL-B) is the most common lipase for organic synthesis, 
already applied in industrial synthesis by Bayer and BASF. In fact, BASF has developed an 
immobilization procedure for CAL-B, thus reducing the need for high catalyst 
concentration.86,87. Nevertheless, the more recent use of CAL-B in the DKR of primary 
amines is highlighted for its high yield, and metal complexes are commonly used in the ester 
hydrolysis. The synthesis of a norsertraline precursor (56) by the DKR of (55) with CAL-B 
and a ruthenium catalyst was reported with high yield (70%) and exceptional e.e. (99%), as 
seen in Scheme 12.88 
 
Scheme 12. Chemoenzymatic synthesis of norsertraline (57). 
Amine oxidases (AO) can also be used for the deracemisation of chiral amines. AO are 
oxidoreductases with important physiological functions in detoxification, cell growth, 
signalling and biosynthesis of alkaloids. They are found in numerous organisms and can be 
classified in two types: type I enzymes, copper-dependent, and type II enzymes, flavin-                   
-dependent. Type I AOs use copper and pyrroloquinoline quinone as co-factors and the 
formed imine remains covalently bound to the protein in the end of the reaction, limiting 
their applicability in biocatalysis. Type II AOs, on the contrary, are flavin-dependent and 
have been extensively used in enzymatic synthesis (E.C. 1.4.3.4).89  
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Several flavin adenine dinucleotide (FAD)-dependent AOs have been reported so far, 
including diamine oxidase90, several amino acid oxidases91 and 6-hydroxy-D-nicotine 
oxidase (HDNO). HDNO (E.C. 1.5.3.6) is a 49kDa monomeric enzyme found in some soil 
bacteria, such as Arthrobacter nicotinovorans, where it is a key enzyme in the degradation 
of nicotine. It has been assigned to the p-cresol methylhydroxylase-vanillyl-alcohol oxidase 
family and, remarkable, stands as the first discovered enzyme with the FAD co-factor 
covalently bound.92 Nowadays, it is estimated that approximately 10% of all flavoproteins 
have a covalently bond co-factor, significantly increasing the enzymes’ redox potential, 
protein stability and preventing co-factor release.93 
Crystal structure analysis has shown that HDNO possesses a large active centre, capable of 
accommodating additional substrates. In fact, a recent article by Heath, et. al. has studied the 
substrate scope of HDNO from Arthrobacter nicotinovorans and found it to be active with 
8 different amines, including substituted derivatives of nicotine. Moreover, a double mutant 
was engineered and used in the deracemisation of additional tetrahydroisoquinoline (58, 60 
and 61) and tryptoline (59) derivatives (Figure 11).94  
 
Figure 11. Deracemisation of tetrahydroisoquinoline and tryptoline derivatives with the 
E350L/E352D HDNO mutant. 
Monoamine oxidase (MAO) remains one of the most important AO, referred as “the mother 
of all amine oxidases” in a book published by SpringerMedicine.95 It catalyses the oxidative 
deamination of biogenic primary amines by producing H2O2. In humans, MAO exists mainly 
in the brain and peripheral tissues in the form of two isozymes: A and B. Although similar 
in sequence (70% sequence identity), these two isozymes differ in their accepted substrates 
and functions in the brain: MAO A shows higher affinity towards serotonin (62), 
norepinephrine (64) and dopamine (20) and has been related to aggressiveness while             
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MAO B has a higher affinity for phenylethylamine (63), benzylamine (65) and dopamine 
(20) and has been implicated in Parkinson’s disease (Figure 12).96 
 
Figure 12. Common MAO A and MAO B natural substrates 
Type I and II non-membrane bound MAO can be found in lower eukaryotes, oxidizing 
amines as nitrogen sources. From those, a flavin-dependent MAO from Aspergillus niger 
(MAO-N) has been extensively engineered for biocatalysis. Besides, its importance in the 
work here presented justifies the separate description that follows.97 
 
1.2.4 Monoamine oxidase from Aspergillus niger 
MAO-N was first cloned in 1995 by Schilling et al. with a butylamine-induced culture. In 
fact, the article suggests this enzyme as an evolutionary prototype of mammalian MAO-A 
and MAO-B.97 The same author readily cloned this enzyme in E-coli, reporting a length of 
495 amino acid residues correspondent to 55.6 kDa.98 
As previously stated, MAO-N is a FAD-dependent enzyme, but the mechanism through 
which the redox reaction occurs is still subject to controversy. According to our research, a 
computational study by Erdem et al. supports the polar nucleophilic mechanism proposed 
by Miller and Edmondson shown in Scheme 13. The authors found good correlations 
between the experimental reaction rate and activation energy of MAO-A with p-substituted 
benzylamines and quantum chemical calculations based on this mechanism.  99 
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Scheme 13. Modified polar mechanism for amine oxidation  
1.2.4.1 Crystal structure and active site 
As far as we can ascertain the crystal structure of MAO-N wild type (wt) has never been 
determined. Yet, Atkin et al. reported and analysed the structure of MAO-N D5, with five 
amino acid substitutions, back in 2008 (Figure 13). It is reported that its asymmetric unit is 
constituted by eight monomers each containing 17 α-helices and 21 β-sheets. Moreover, this 
enzyme shows a similar structure to human MAO near the FAD molecule, both showing a 
~30º angle in the isoalloxazine ring. MAO-N D5 also lacks a protruding helix present in 
MAO A and B, thought responsible for membrane binding.100 
The active site of MAO-N is formed by a single large hydrophobic cavity, on the re face of 
FAD’s ring system, and an “aromatic cage”, containing the co-factor and formed by the 
flavin and W430 and F466 amino acid residues. In fact, it is suggested these amino acids are 
essential to the enzyme’s activity, playing significant steric and electronic functions. The 
hydrophobic pocket extends to the protein surface, and three hydrophobic residues, M242, 
M246 and Y238, are proposed as a “gate” for substrate entrance into the active site. It is 
suggested that the hydrophobic character of this entrance channel can be determinant in 
MAO-N’s selectivity towards small cyclic non-polar substrates.  
Furthermore, it is noted that the amino acid residues mutated in all directed evolution 
experiments directly interfere with the active site, and Atkin et al. note that two of the most 
significant mutations alter the aromatic cage and the substrate binding site, possibly 
improving the electronic distribution and releasing steric constraints, respectively.100 
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Figure 13. Proposed hydrophobic cavity in MAO-N D5. Right: residues forming the 
hydrophobic cavity in green and the FAD co-factor in blue. Adapted from Atkin et al..100  
1.2.4.2 State of art: increasing the substrate scope of MAO-N by directed 
evolution 
Research in the use of MAO-N for biocatalysis started with substrate scope studies by Sablin 
et al.101, who limited the activity of this enzyme to a few simple primary amines. Since then, 
a remarkable work by the Turner group at the Manchester Institute of Biotechnology (MIB) 
has increased its utility by consecutives rounds of directed evolution and established efficient 
oxidation and deracemisation procedures. 
The first reported evolutionary studies on MAO-N date back to 2002, when Alexeeva et al 
used random mutagenesis and a solid phase colorimetric assay to discover a single MAO-N 
D1 mutant - N336S - with increased activity towards α-methylbenzylamine (AMBA) (66). 
In the same article, a DKR experiment with a reducing agent, ammonia-borane complex, 
was first reported for the synthesis of (R)-AMBA (68) with 77% yield and 93% e.e. (Scheme 
14).102 Soon after, the substrate scope of this mutant was determined, showing high activity 
toward a broader range of primary amines, preferably flanked by a small alkyl group and a 
bulky aryl group. Significant activity of any MAO-N variant towards                                                     
1-methyltetrahydroisoquinoline (1-MTQ), a secondary amine, is first stated in this article.103 
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Scheme 14. Dynamic kinetic resolution of AMBA 
Additional random mutagenesis was performed on MAO-N D1 by Carr et al. in order to 
increase MAO-N’s activity towards secondary amines. A double mutant - M248K/I246M - 
was found with high activity towards secondary amines and named MAO-N D3. This mutant 
presented a 5-fold increase in activity for 1-MTQ (69) relative to MAO-N D1. A small-scale 
deracemisation reaction was performed with this substrate to afford (R)-1-MTQ (71) with 
71% yield and 99% e.e. over 48 hours (Scheme 15). Moreover, immobilization of the 
enzyme in Eupergit C resin increased the yield to 95% while maintaining the e.e., but 
required 98 hours for completion.104 
 
Scheme 15. DKR in the deracemisation of 1-MTQ. 
Dunsmore et al. continued the previous work by screening a recently found MAO-N D5 
mutant – I246M/N336S/M348K/T384N/D385S – with a number of secondary and tertiary 
amines, reporting remarkable activity with N-methylated substrates. This new mutant was 
used in a chemoenzymatic reaction for the synthesis of chiral secondary amines (74) from 
prochiral aminoketone compounds (72) (Scheme 16).105  
Also, an article by Foulkes et al. reports the use of MAO-N D5 with nanoscale bioreduced 
Pd(0) particles/H2 for the deracemisation of 1-MTQ with 96% yield. However, it is stated 
that separate reactions are required for the oxidation and reduction steps, complicating the 
overall procedure.106 
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Scheme 16. Chemoenzymatic route for the synthesis of (R)-2-phenylpyrrolidine 
Surprisingly, an article outside Turner’s group was found regarding the directed evolution 
of MAO-N D5 for the deracemisation of mexiletine (75) (Figure 14). By SDM based on the 
results from docking studies, and posterior screening assays, Chen et al. reported three new 
mutants based on MAO-N D5 – F210V/L213C, F210V/I367T and F210V/L213C/I367T – 
with enhanced activity towards this substrate. According to their studies, the F210V 
mutation can widen both the binding cavity and entrance channel, and L213C and F210V 
mutations combined can cause the formation of a new disulphide bond that enlarges the 
binding pocket by disulphide bond stretching.107 
 
Figure 14. Structure of mexiletine 
Meanwhile, Rowles et al. further improved MAO-N activity for the deracemisation of 
crispine A.108 Four target residues from the entrance channel were identified by molecular 
modelling for their steric interaction with this substrate, and the parent enzyme subjected to 
two rounds of saturated double mutagenesis and solid-phase screening. A new mutant, 
MAO-N D9 C, was found with a 990-fold increase activity towards crispine A (76). The 
additional mutations – F210L/L213T/M242Q/M246T – widened the entrance channel by 
changing the orientation of the side-chains in these residues. Lastly, the deracemisation of 
crispine A with MAO-N D9 C is reported with >99% e.e. within 2 hours (Scheme 17). 
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Scheme 17. Deracemisation of crispine A with MAO-N D9 C 
Four enzymatic cascade reactions have been reported for the synthesis of highly enantiopure 
primary and secondary amines with great yield, by the use of additional enzymes (ω-TA, 
xanthine dehydrogenase (XDH) or IRED) or an artificial transfer-hydrogenase (ATHase). A 
brief summary of these reactions can be seen in Scheme 18.80,109–111  
  
Scheme 18. Enzymatic synthesis of enantiopure chiral amines with MAO-N D5 or D9 
variants 
The last reported MAO-N mutant within the literature is MAO-N D11, surprisingly obtained 
by a simple change in an already mutated residue in MAO-N D9 – W430H to W430G.112 It 
proved effective for the deracemisation of bulky amines such as                                                                  
1-phenyltetrahydroisoquinoline. This new mutant has been recently explored for the 
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deracemisation of 1-benzyl-N-methyltetrahydroisoquinoline derivatives (83), with excellent 
e.e. and good yields, and the synthesis of protoberberines (84) by a MAO-N D11/Berberine 
bridge enzyme (BBE)/NH3
.BH3 redox cascade, with excellent e.e. and yields (Scheme 
19).113,114 
 
Scheme 19. MAO-N D11 catalysed synthesis of enantiopure                                                                        
1-benzyltetrahydroisoquinoline derivatives. 
A recent unpublished work by Jane Kwok et al. at the Manchester Institute of Biotechnology 
reports a rational non-randomized method for the directed evolution of MAO-N starting 
from MAO-N D5.115 With it, they expect to achieve a more efficient search of the enzyme’s 
functional space in the future. This work in progress involves the creation of double mutant 
libraries in every segment of MAO-N’s secondary structure and use a solid-phase screening 
assay to determine the mutants responsible for an increased activity with α-AMBA. The 
researcher also states that the gene can be divided into three main regions: high variations, 
amino acid residues where mutations do not affect the enzyme’s activity; high conservations, 
where any mutation reduces or completely eliminates enzyme activity; and strong selections, 
where a tendency is found towards specific mutations when sequencing the mutants with 
increased activity. These last areas have enormous potential in engineering and, so far, nine 
residues have been identified that show strong selection – C50T, S81T, S81C, Y86T, F128L, 
S205T/S206N, A266V, A289V and I356V. Although most of these residues are thought to 
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alter the entrance channel or the position of the FAD tricyclic ring, some are distal to the 
active site and therefore may present an oligomer formation or solubilisation role. An image 
of the MAO-N D5 gene divided by these regions can be seen in Figure 15.  
 
Figure 15. Summary of the solid phase screening of MAO-N mutants, with the MAO-N 
gene marked with the previously mentioned areas: high variations, in blue, high 
conservations, in white with green letters marking the majority residue, and strong 
selections, in yellow.115 
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1.3 SCOPE OF THIS WORK 
Biocatalysis represents one of the most promising routes towards a sustainable future in the 
industrial production of fine chemicals. Particularly, monoamine oxidase from Aspergillus 
niger has been consistently engineered for the oxidation and deracemisation of chiral amines. 
Nevertheless, a limited substrate scope is still reported, and further evolution of this enzyme 
is still undergoing. As so, and given the opportunity presented by working with the Turner 
group, highly experienced in MAO-N expression and evolution, in this work we aimed to 
further develop this high potential oxidase, and explore its potential use in cascade reactions. 
To accomplish these goals, we: 
i) Established a target scaffold, THIQ, and devised a library of compounds capable of 
fully assessing MAO-N’s substrate scope. The library used contained THIQs with a 
methyl substituent in all the positions of the bicyclic ring as well as                                            
6,7-dimethoxytetrahydroisoquinoline (DMTHIQ) and 6,7-dimethoxy-1-                                    
-methyltetrahydroisoquinoline (1-M-DMTHIQ), as seen in Figure 16; 
 
Figure 16. Tetrahydroisoquinoline substrates used within the scope of this work. 
 
ii) Expressed MAO-N D5, D9 and D11 in E. coli and purified sufficient enzyme for the 
specific activity assays. Expression of MAO-N D9 in P. pastoris was also attempted; 
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iii) Perfected a colorimetric screening assay and used it to assess the activities of 11 MAO-
N variants (Table 1) – MAO-N D5, D9, D11 and eight promising variants from the 
previously mentioned Jane Kwok et al. work115, from now on defined as MAO-N D12 
(A-H) variants – with all the substrates previously mentioned; 
 
Table 1. MAO-N variants used in the specific activity assays. The mutations 
I246M/N336S/M348K/T384N/D385S are present in all the variants below. 
MAO-N 
variant 
C50 S81 F128 
S205 
/S206 
F210 L213 M242 I246 A266 A289 I356 W430 
D5 - - - - - - - - - - - - 
D9 - - - - L T Q T - - - H 
D11 - - - - L T Q T - - - G 
D12 (A) - - - - - - - - V - - - 
D12 (B) T - - - - - - - - - - - 
D12 (C) - - L - - - - - - - - - 
D12 (D) - - - - - - - - - - V - 
D12 (E) - C - - - - - - - - - - 
D12 (F) - T - - - - - - - - - - 
D12 (G) - - - T / N - - - - - - - - 
D12 (H) - - - - - - - - - V - - 
iv) Used the data obtained from the previous experiments to develop a new MAO-N D13 
mutant, based on MAO-N D9, and tested its ability to oxidize and deracemize 1-M-
DMTHIQ; 
v) Used MAO-N D5, D9, D11 and HDNO E350L/E352D - developed by Heath et al.94 
and from now on simply designated as “HDNO” - in the deracemisation of the chiral 
substrates aforementioned; 
vi) Presented the proof of concept for a novel one-pot three step synthesis of unnatural 
tetrahydroisoquinoline amino acids by the oxidation, cyanation and selective 
hydrolysis of their C1 unsubstituted counterparts
  
 
CHAPTER 2. EXPERIMENTAL 
SECTION 
  
 
 
Chapter 2. experimental section 
39 
 
GENERAL INFORMATION 
MAO-N D5, D9 and D11 genes in pET16b plasmids were obtained from the plasmid library 
of the Manchester Institute of Biotechnology. Empty pPicZα C vectors from Invitrogen™ 
were used for protein expression in P. pastoris. Competent E. coli cells - BL21(DE3), NEB® 
5-alpha and Rosetta™ - were purchased from New England Biolabs® Inc.. Moreover, 
competent P. pastoris GS115 and X-33 cells from Invitrogen™ had been previously grown 
in the MIB and stored at -80ºC for use in this project. 
Substrates used in the specific activity assays and biotransformations were either 
commercially available by Sigma Aldrich and Flurochem or supplied by Orion Pharma, UK. 
The solvents used were high-performance liquid chromatography (HPLC) grade or 
analytical grade.  
1H and 13C NMR spectra were recorder on a Bruker Avance 400 (400.1 MHz for 1H and 
100.6MHz for 13C) without additional internal standard. Chemical shifts are reported in δ 
(ppm) and multiplicities defined as follows: s – singlet; d – doublet; t – triplet; m – multiplet. 
HPLC measurements were performed on Agilent machines equipped with diode arrays and 
1100 or 1200 series modules. Columns and conditions used in this work are indicated 
separately for each run.  
2.1 PLASMID SELECTION 
2.1.1 pET16b (E. coli) 
A 5711 base pair (bp) long pET16b vector was used in the expression of MAO-N variants 
(Figure 17). Apart from the origin of replication (ori), this plasmid first presents a gene 
encoding resistance to the antibiotic ampicillin (F), allowing for the selection of successful 
transformants in a medium with this particular antibiotic. Then, a lacI gene and a lac operon 
(C) are present and lead to a regulation of protein expression by lactose. LacI encodes for 
the expression of the lac repressor protein, which binds to the lac operon and stops the 
transcription of the gene of interest. The presence of either lactose or isopropyl β-D-1-                      
-thiogalactopyranoside (IPTG) induces protein expression by interacting with the lac 
repressor and preventing its binding to the operon.  
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Both the lac operon and the gene of interest are inserted between the T7 promoter (B) and 
T7 terminator (E), responsible for its the transcription by the T7 RNA polymerase present 
in the E. coli strains used. Although not naturally present in E. coli, this polymerase has been 
engineered into the bacteria as it synthesizes RNA at a much faster rate than the native 
polymerase. Finally, a chain of 10 histidine codons (D) is included and transcribed with 
MAO-N. In this manner, the histidines are translated in the end of the wanted protein and its 
strong coordination with Ni+2 can be used for a quick purification procedure.116 
 
Figure 17. Scheme of an empty pET16b plasmid. (A) Lac promoter; (B) T7 promoter; (C) 
Lac operon; (D) 10x Histidine Tag; (E) T7 terminator; (F) Ampicillin resistance marker. 
2.1.2 pPicZα C (P. pastoris) 
In this work a 3.6 kilobases (kb) pPicZ-α C vector was used for the insertion of MAO-N D9 
gene into the genome of P. pastoris (Figure 18). An increased transformation and expression 
complexity is found in this organism as the procedure involves the incorporation of the target 
gene into the organism’s genome. As so, some additional features are required in the 
plasmid.62  
First, an alcohol oxidase 1 (AOX1) promoter and terminator are used, allowing for a 
methanol induced protein expression. Then, the presence of a α-factor, expressed with the 
desired gene, causes the segregation of MAO-N D9 to the extracellular medium. Moreover, 
a 6x Histidine Tag is used to facilitate protein purification. Finally, an antibiotic (Zeocin™) 
resistance marker is introduced to allow the selection of successful transformants.62 
Chapter 2. experimental section 
41 
 
 
Figure 18. Scheme of an empty pPicZα C plasmid. Adapted from Lezdey et al..117 
2.2 TRANSFORMATION PROTOCOLS 
2.2.1 E. coli BL21 (DE3) 
Available plasmid DNA of D5, D9 and D11 mutants of MAO-N in a pET16b vector were 
transformed into chemically competent E. coli BL21(DE3) cells by heat shock. 
Approximately 50 ng of circular plasmid DNA were added to 50 µL of cells, followed by 
thawing on ice for 30 minutes. The cells were heat shocked for 40 seconds at 42°C and left 
on ice for 2 minutes to reduce cell damage. Next, 300 µL of super optimal broth with 
catabolite repression (SOC) media was added and the mixture was left incubating for one 
hour at 37°C. The resulting culture was spread on lysogeny broth (LB) plates with ampicillin 
(100 mg/L) and left to grow overnight at 37°C. 
2.2.2 E. coli NEB® 5-alpha 
A similar procedure was used to transform MAO-N D9 plasmid DNA into a Bio-Rad NEB® 
5-alpha cloning strain. Low salt LB plates with Zeocin™ were required for a correct 
antibiotic selection when transforming MAO-N in a pPicZα C vector. 
2.2.3 E. coli Rosetta™ (DE3)  
The transformation was carried out using the procedure previously described in point 2.2.1. 
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2.2.4 P. pastoris GS115 
Transformation of the MAO-N D9 gene into Pichia pastoris GS115 cells was achieved by 
electroporation of the pPicZα C plasmid containing the gene of interest. First, circular 
plasmid DNA was linearized with a restriction enzyme digestion. 2 µL of a suitable 
restriction enzyme – PmeI, New England Biolabs® Inc. - was added to approximately 20 µg 
of plasmid DNA in 30 µL of water. After overnight incubation at 37°C, linearized plasmid 
DNA was purified using a QIAquick PCR Purification Kit. 
P. pastoris GS115 cells were grown on a LB plate for 96 hours at 30°C. A single colony was 
used to incubate 5 mL of YPD (yeast extract peptone dextrose) media in a 50 mL falcon tube 
and grown overnight at 30°C. Then, 500 mL of fresh medium in a 2 litre Erlenmeyer were 
inoculated with 0.1 mL or 0.2 mL of the overnight culture and left growing at 30°C until an 
OD600 between 1.3 and 1.5 is reached (approximately 16 hours). The incubation of two 
separate media with different amounts of cells allowed us to choose the one closer to the 
desired optical density (OD) for transformation. This value is extremely important as a 
higher cell density, passing the log phase, can lead to a reduction in cell viability after 
electroporation. 
Cells were then centrifuged at 1500 g and 4°C for 10 min. The cell pellet was collected and 
resuspended in 500 mL of ice-cold, sterile water and centrifuged again under the same 
conditions. This step was repeated one more time with 250 mL of water. 
Next, cells were resuspended in 20 mL of ice-cold, sterile 1 M sorbitol, transferred to a 50 
mL falcon tube and centrifuged again. Finally, the cells were resuspended in 1 mL of 1 M 
sorbitol to a final volume close to 1.5 mL and kept on ice to be used within the hour. 
For the electroporation step, 80 µL of cells were mixed with 5-10 µg of linearized DNA in 
an ice-cold 0.2 cm electroporation cuvette. After 5 min incubation on ice, the cells were 
pulsed at 2,500V for 5 ms using a Gene Pulser MXcell™ Electroporation System, Bio-Rad 
Laboratories. Ice-cold 1 M sorbitol (1 mL) was immediately added and cells left to 
regenerate for one hour at 30ºC without shaking. The mixture was then centrifuged and cells 
resuspended in 300 µL of sorbitol. 100 µL were spread on YPD plates containing 100, 500 
and 1000 mg/L of Zeocin™. Higher antibiotic concentration allowed for a better selection 
of multi-copy recombinants. The plates were incubated, protected from light, at 30°C for 5 
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days. Successful insertion was verified by Touchdown PCR using insert primers from the 
ligation independent cloning followed by agarose gel electrophoresis. 
2.2.5 P. pastoris X-33 
A similar procedure to the one used on 2.2.4 was applied to this transformation. 
2.3 GROWTH OF MAO-N IN E. coli 
A single colony was used to inoculate a 5 mL pre-culture of LB media with ampicillin                
(100 mg/L), which was grown at 37°C overnight. 2 L Erlenmeyer flasks containing 500 mL 
of Terrific Broth (TB) medium with ampicillin (100 mg/L) were inoculated with 2 mL of 
pre-culture and incubated for 48 hours at 25°C. Additional experiments with different 
incubation parameters were performed for MAO-N D9 and can be found in Table 2. 
One additional experiment was attempted using IPTG induction. To a 2 L Erlenmeyer flask 
containing 500 mL of TB medium with ampicillin (100 mg/L) was added 2 mL of pre-culture 
and incubated until an OD of 0.6-0.8 was reached. 1 M IPTG was added to a final 
concentration of 0.2 mM and the culture incubated at 20ºC overnight.  
After incubation, the cells were collected by centrifugation at 4000 rpm and 4°C for 30 
minutes, followed by resuspension in 15 mL of phosphate buffer (pH 8.0, 100 mM) and 
further centrifugation. The cell pellet was collected and collected and stored at -20°C. In 
standard conditions, approximately 10 g of cell paste were obtained per incubation.  
Table 2. Experiment parameters for MAO-N D9 expression in E. coli 
Experiment E. coli strain Medium Time (h) Temperature (ºC) 
1 BL21(DE3) TB 48 37 
2 BL21(DE3) TB 24 37 
3 BL21(DE3) TB 72 25 
4 BL21(DE3) TB 24 30 
5 BL21(DE3) TB 48 30 
6 BL21(DE3) LB 48 30 
7 NEB® 5-alpha TB 48 30 
8 Rosetta™ TB 48 30 
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2.4 PURIFICATION OF MAO-N 
One gram of cell paste was resuspended in 10 mL of buffer A (100 mM KPi, pH 7.7, 5 mM 
imidazole) and cooled to 4°C. Cell lysis was achieved through ultrasonication (20 s on, 20 s 
off, 20 cycles). After centrifugation (20000 rpm, 4°C, 30 min) the supernatant was loaded 
on a column with approximately 1 mL of Ni-NTA Agarose from QIAGEN. The column was 
closed and mixed for 1 hour. After eluting and collecting the flow-through, 10 mL of buffer 
B (100 mM KPi, pH 7.7, 30 mM imidazole) was added the remove unbounded protein and 
collected as the wash-through. Finally, the protein was eluted with 10 mL of buffer C               
(100 mM KPi, pH 7.7, 250 mM imidazole) and collected in 1 mL fractions. 
All fractions were analysed by SDS-PAGE to ensure a correct purification. MAO-N 
containing fractions were pooled and concentrated using a Sartorius Vivaspin 20 spin 
column (30 kDa cut-off) with centrifugation at 4000 rpm for 20 minute cycles until a final 
volume near 2.5 mL was reached. The solution was then desalted using a PD-10 Sephadex 
column (GE Healthcare) to a final volume of 3.5 mL in phosphate buffer. 
2.5 SDS-PAGE 
Polyacrylamide gel electrophoresis (PAGE) is a technique used to separate macromolecules, 
for identification and quantification purposes, by its mobility in a polyacrylamide gel when 
subjected to an electric current. With proteins, sodium dodecyl sulphate (SDS) is commonly 
used to cause complete denaturation and simultaneously induce a negative charge to the 
protein, allowing a separation based mainly on size.  
In this work 20 µL of 2x Laemli Buffer (MicroMol) were added to 20 µL of protein sample. 
Proteins were denatured in a heat block at 104°C for 10 min and 20 µL of the resulting 
solution was applied to each well of the gel. A 10 to 180 kDa PageRuler™ Prestained Protein 
Ladder was added to the first well to confirm the expected weight of the protein and the gel 
run for 30 min at 230 V. 
2.6 PROTEIN QUANTIFICATION: BRADFORD PROTEIN ASSAY 
Purified protein was quantified using a Bradford protein assay. This assay is based in the 
binding of a dye (Coomassie Brilliant Blue G-250) to the protein, generating a shift in the 
absorption spectrum to a maximum of 595 nm. As so, it is possible to estimate the protein 
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concentration on a given sample by comparison of the absorption at 595 nm with one of a 
standard protein with a known concentration – in this case bovine serum albumin (BSA). 
The calibration curve used is presented in Equation 1 and the corresponding graph can be 
seen in Figure A1.1. 
𝑦 = 0.6543𝑥 + 0.3441  (𝑅2 = 0.994) 
Equation 1. Calibration curve for protein concentration in the Bradford protein assay 
In this assay, 200 µL of 1X Bradford reagent (Bio Rad) was added to 10 µL of either BSA 
or sample in a 96 well plate. After incubating at room temperature for at least 10 minutes, 
the absorbance at 595 nm was measured with a Tecan Infinite® M200 microplate reader.  
2.7 SPECIFIC ACTIVITY ASSAYS 
In a 96 well plate, 50 µL of horseradish peroxidase (HRP) (0.20 mg/mL in phosphate buffer), 
50 µL of a 10 mM solution of substrate in phosphate buffer (pH=8.0) and 50 µL of solution 
A were added to each well. 50 µL of a 0.10 or 0.05 mg/mL enzyme solution was quickly 
added and the absorbance at 510 nm was monitored at 30°C for the next 20 min using a 
Tecan Infinite® M200 microplate reader. Two replicas of each assay were made and the 
average value and standard deviation used in further calculations. 
Solution A: Previously mixed solution of 37.5 µL of 4-aminoantipirine (4-AAP) (50 mg/mL 
of water) and 150 µL of 2,4,6-tribromo-3-hydroxybenzoic acid (TBHBA) (75 mg/mL of 
DMSO), diluted to 1,500 mL with phosphate buffer. 
2.8 DNA PROTOCOLS 
2.8.1 Preparation of plasmid DNA from E. coli 
A single colony was used to inoculate a 5 mL LB culture with the appropriate antibiotic. The 
culture was incubated overnight at 37ºC and plasmid DNA was isolated using the QIAprep 
Spin Miniprep Kit, QIAGEN. In order to increase final plasmid concentration, 35 µL of 
nuclease-free warm water were used to elute the DNA.  
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2.8.2 Determination of DNA concentration 
DNA concentration was calculated using a NanoDrop ND-1000 spectrophotometer. The 
purity of the sample was assessed by the difference between in the absorbance spectrum of 
DNA – maximum at 260 nm - and proteins – maximum at 280 nm. A ratio of A260/A280 
between 1.8 and 2.1 was usually obtained and falls into standard values for pure DNA 
samples. 
2.8.3 Agarose gel electrophoresis 
An agarose gel consists in a matrix of polymeric oligosaccharides with pores that allow the 
passage of biomolecules. An electric current is applied that induces a migration of DNA 
towards the anode through the pores of the gel, generating a separation by molecular weight. 
In this experiment, a 1% agarose gel (0.5 g of agarose dissolved in 50 mL of TAE                       
(tris-acetate-EDTA) buffer) was prepared and allowed to solidify in the cast. Next, 5 µL of 
reaction mixture – typically the direct result of a PCR experiment – were mixed with 1 µL 
of 6x DNA Loading Dye and transferred to the agarose wells along with a 1 kb Prestained 
DNA Ladder. The gel was then run in TAE buffer at 100 V for 30 min and the results 
visualized under ultraviolet light. 
2.8.4 Ligation independent cloning: insertion of MAO-N D9 gene into pPicZα 
C empty vector 
Ligation independent cloning is a technique developed as an alternative to restriction 
enzyme/ligation cloning. It discards the need for a time consuming ligation step by 
amplifying both the insert and the empty plasmid with overhangs, that is, sequences of DNA 
non-complementary to the DNA being amplified. These overhangs are, however, 
complementary to each other, as described in Figure 19, and ligate once the results of both 
amplifications are combined. When all four overhangs are joined together, the desired 
circular plasmid with the gene of interest is obtained.  
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Figure 19.  Ligation independent cloning for the insertion of MAO-N D9 gene into a pPicZα 
C empty vector 
Primers for both the insert and the empty vector are presented in Table 3. Amplification of 
both DNA sequences was done by Phusion® PCR, according to Tables 4 and 5, and purified 
with a QIAGEN PCR purification kit. Successful amplification was verified by agarose gel 
electrophoresis and the linearized DNA was stored at -20ºC for further use. 
Table 3. List of the primers used in the ligation independent cloning. 
Primer 
name 
Sequence 
Forward 
Insert 
TCTCGAGAAAAGAGAGGCTGAAGCTATGACCTCCCGTGACGGTTACCAGT 
Reverse 
Insert 
AATGATGATGATGATGATGGTCGACCAAACGAGCCTTCACCTCCCTCTTC 
Forward 
Vector 
GAAGAGGGAGGTGAAGGCTCGTTTGGTCGACCATCATCATCATCATCATT 
Reverse 
Vector 
ACTGGTAACCGTCACGGGAGGTCATAGCTTCAGCCTCTCTTTTCTCGAGA 
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Table 4. Phusion® PCR mix 
Component HF buffer PCR 
H2O 36.5 µL 
5 x Phusion HF buffer 10 µL 
10 mM dNTPs 1 µL 
Primer mixture 10 mM 1 µL 
MAO-N D9 / pPicZα C plasmids 1 µL 
Phusion DNA polymerase 0.5 µL 
Table 5. Phusion® PCR cycle program. A) MAO-N D9; B) pPicZα C. 
Cycle step Temperature Time Cycles 
Initial denaturation 98ºC 30 s 1 
Denaturation 
Annealing 
Extension 
98ºC 
58ºC 
72ºC 
30 s 
30 s 
30s (A)/ 2 minutes (B) 
30 cycles 
Final extension 72% 5 minutes 1 
Both insert and vector DNA with overhangs were later mixed and incubated at room 
temperature until only circular plasmid was found on the agarose gel electrophoresis. The 
resulting plasmid was directly transformed in E. coli NEB® 5-alpha and an overnight culture 
(250 rpm, 37 ºC) was spread on a low salt LB/Zeocin™ plate and incubated at 37 ºC. 
Several colonies were chosen and used in an overnight culture at 37 ºC and 250 rpm. Plasmid 
DNA was purified and stored for future use in linearization/electroporation. 
2.8.5 Site-directed mutagenesis 
A site-directed mutagenesis experiment was performed for the mutation of the S205 and 
S206 amino acids of MAO-N D9. A set of primers was designed in such a way so the mutated 
region rested in the middle of the forward primer. This primer possessed two non-
complementary bases in its sequence that, despite not pairing with the DNA, are transcribed 
and alter the enzyme’s protein sequence.  
The following 25 base-long mutagenic primers (Table 6) were ordered through Eurofins 
Scientific© and dissolved to a concentration of 100 µmol/mL in nuclease-free water. 
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Table 6. List of mutagenic primers used in the double mutation (mutagenic base pairs in 
bold). 
Primer name Sequence 
Forward primer CTTAATGAACGGACTAATCTGGAAGCGTTGATATTGACC 
Reverse primer GCTCAACTCATCCCGGATTTGATCAATCCG 
Mutant strand synthesis (PCR) was prepared in 0.2 mL PCR tubes with the reagents 
presented in Table 7. Both High-Fidelity and GC buffers were used to ensure a good 
amplification. The cycle program used follows in Table 8. 
Table 7. Site-directed mutagenesis PCR reaction mix 
Component HF buffer PCR GC buffer PCR 
H2O 36.5 µL 35 µL 
5 x Phusion HF buffer 10 µL - 
5 x Phusion GC buffer - 10 µL 
10 mM dNTPs 1 µL 1 µL 
Primer mixture 10 mM 1 µL 1 µL 
Dimethyl sulfoxide - 1.5 µL 
MAO-N D9 plasmid DNA 1 µL 1 µL 
Phusion DNA polymerase 0.5 µL 0.5 µL 
Table 8. Site-directed mutagenesis PCR cycle program 
Cycle step Temperature Time Cycles 
Initial denaturation 98 ºC 30 s 1 
Denaturation 
Annealing 
Extension 
98 ºC 
58 ºC 
72 ºC 
30 s 
30 s 
2 minutes 
30 cycles 
Final extension 72 ºC 5 minutes 1 
Success in the amplification was verified by agarose gel electrophoresis. Resulting DNA 
was purified with a Qiagen PCR purification kit and transformed in E. coli cloning strain 
(NEB® 5-alpha) according to the protocol above. 
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After selective cell growth in LB plates with ampicillin, four random colonies were selected 
and used to incubate a 5 mL LB/Ampicillin medium which was grown overnight at 250 rpm 
and 37 ºC. Plasmid DNA was purified, concentrated and sent to sequencing to confirm a 
successful mutation. Finally, the mutated plasmid DNA was transformed in E. coli 
BL21(DE3) and cells grown according to the protocol above. 
2.9 BIOTRANSFORMATIONS 
2.9.1 Amine deracemisations with MAO-N D5/D9/D11 or HDNO 
To a 15 mL falcon tube with 5 mL of a 10 mM solution of substrate in phosphate buffer            
(pH 8.0), 0.5 grams of cell pellet were added. When required, the substrate was previously 
dissolved in 50 µL of DMSO. Five equivalents of ammonia-borane complex (BH3
.NH3) 
were also introduced and pH adjusted to 8 by addition of 1M HCl. 
The reaction mixture was incubated at 250 rpm and 37 ºC and the e.e. monitored by HPLC, 
working up small samples at appropriate time intervals. To a 250 µL aliquot of reaction 
mixture 40 µL of 5M NaOH and 250 µL of TBME were added. The solution was vigorously 
mixed and centrifuged at 13000 rpm for 1 min. The organic phase was separated, dried with 
anhydrous sodium sulphate and run on a normal-phase HPLC. Conversion was verified by 
normal-phase HPLC, by comparison with standards. When not commercially available, 
imine compounds were synthesized by large scale biotransformations and conversion 
determined by 1H NMR. These were directly used as standards for HPLC. 
2.9.2 MAO-N D9/D11 or HDNO imine formation reactions 
A similar procedure to the above mentioned was used for these biotransformations. 0.1 
grams of cell pellet were added to 1 mL of a 10 mM solution of substrate in phosphate buffer. 
The reactions were incubated at 250 rpm and 37 ºC and monitored by HPLC as previously 
described. When not commercially available, imine compounds were synthesized by large 
scale biotransformations and conversion determined by 1H NMR. These were directly used 
as standards for HPLC. 
Large scale biotransformations were done in a 5 mL scale and extracted after 48 hours with 
3 x 5 mL of ethyl ether. The organic phase was dried and concentrated, and the product was 
analysed by 1H and 13C NMR. 
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2.9.3 HPLC analysis: determination of the relative response factor 
The relative response factor (RRF) allows an accurate comparison of the concentration of 
two compounds in an HPLC run by its peak area. It can be calculated according to Equation 
2, whose values can be obtained from the HPLC runs of standards of each compound. 
𝑅𝑅𝐹(𝐴/𝐵) =
𝑃𝑎/𝐶𝑎
𝑃𝑏/𝐶𝑏
 ,  where P is the peak area, C the concentration of the sample injected and 
A and B different compounds. 
Equation 2. Relative response factor 
The determination of the RRF between 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
(A) and 6,7-dimethoxy-1-methyltetrahydroisoquinoline (B) is presented as an example. In 
Figure 20, equimolar standards of both compounds were run at the HPLC and peak area 
determined. In such conditions as 𝐶𝐴 = 𝐶𝐵, 
𝑅𝑅𝐹(𝐴/𝐵) =
𝑃𝐴
𝑃𝐵
⟹ 𝑅𝑅𝐹(𝐴/𝐵) =
54521.5
19347.8
= 2.82 
 
Figure 20. Normal phase HPLC trace (CHIRACEL® OD-H 250 mm x 4.6 mm, 5 µm, eluent: 
hexane/isopropanol/diethylamine = 90/10/0.1, 1 mL/min, 280 nm) of a 10 mM standard 
solution of either 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (top)or 6,7-dimethoxy- 
-1-methyltetrahydroisoquinoline (bottom). 
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2.9.4 Nitrilase catalysed hydrolysis 
Commercially available lyophilized cell-free extract of six nitrilases was used in the 
following biotransformations. To 1 mL of a 20 mM solution of cyano substrate in phosphate 
buffer (pH 8.0) was added 3 mg of the corresponding enzyme. The mixture was incubated 
at 150 rpm and 30 ºC for 72 hours, after which a sample was taken and analysed by reverse-
phase HPLC. Additional 3 mg of enzyme were added and the reaction was incubated for 
more 48 hours, followed by new HPLC analysis. HPLC samples were prepared by 
centrifugation of a 200 µL aliquot at 13200 rpm followed by a 1:2 dilution of the supernatant 
in methanol and posterior 1:2 dilutions in methanol/water 50/50. Product concentration was 
calculated according to Equation 3, whose graphic can be consulted in Figure A1.2.  
 
𝑦 = 3807𝑥    (𝑅2 = 0.987) 
Equation 3. Calibration curve of tetrahydroisoquinoline-1-carboxylic acid concentration. 
 
2.10 CHEMICAL REACTIONS 
2.10.1 Cyanation of 3,4-dihydroisoquinolines 
A 1 M solution of potassium cyanide (1.5 eq.) was added to a 1.5 M solution of                              
3,4-dihydroisoquinoline in water previously acidified with diluted sulphuric acid, according 
to a procedure by Beumont et al..118 The reaction was left stirring at room temperature for 1 
hour. After extraction with ethyl ether, the yield was determined by 1H and 13C NMR. 
Decomposition of the cyano compounds occurred quickly at room temperature and, as so, 
the product was kept at -4 ºC. 
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3.1 PROTEIN EXPRESSION 
3.1.1 Protein expression in E. coli 
After transforming MAO-N D5, D9 and D11 plasmids into competent BL21(DE3) cells and 
expressing and purifying the protein using the protocol described in Chapter 2, the adequate 
MAO-N variant’s presence was verified by SDS-PAGE (Figure 21). Success was confirmed 
by the presence of a single band in the polyacrylamide gel between 60 and 70 kDa, eluted 
between fractions 2 and 7. With 495 amino acid residues, MAO-N has a molecular weight 
of approximately 60 kDa. 
 
Figure 21. SDS-PAGE gel of MAO-N variant’s purification. The protein ladder, marked at 
75 kDa, was run in the first well, followed by the flow-through (FT), the wash-through (WT) 
and the elution fractions by order. a) MAO-N D5; b) MAO-N D9; c) MAO-N D11. 
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The obtained solutions were subjected to the Bradford protein assay and protein 
concentrations calculated by comparison with a BSA calibration curve (Figure A1.1). 
Results show that 3.5 mL of MAO-N D5, D9 or D11 solutions had a concentration ranging 
from 0.63 to 1.59 mg/mL (Figure 22). Moreover, the increased number of mutations in 
MAO-N D9 and MAO-N D11 seem to difficult enzyme expression. These results were taken 
into account in the specific activity assays that follow. 
 
Figure 22. Protein concentration of MAO-N variants calculated by the Bradford Assay 
Additional expression of MAO-N D9 was attempted with different incubation conditions 
and E. coli strains but, unfortunately, SDS-PAGE analysis showed no significant amount of 
protein after purification. Troubleshooting of this results lead to the analysis of the DNA 
sequence of MAO-N wt, D5 and D9. Large differences were found in the codon frequencies 
of MAO-N wt and MAO-N D5, indicating that the D5 variant had been previously codon 
optimized for expression in E. coli – see 1.2.2.2 for further reference. On the other hand, 
MAO-N D9 sequencing showed this enzyme had not been codon optimized, which could 
justify its low expression in this organism. 
3.1.2 Protein expression in P. pastoris 
P. pastoris is a methylotrophic organism widely used for heterologous protein expression. It 
presents several advantages in its ability to secrete proteins and reach high cell densities. 
Moreover, it is a suitable host to test our hypothesis that MAO-N D9 did not express due to 
a lack of codon optimization, as yeast stands more similar to the native host, Aspergillus 
niger.62 
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In this work, MAO-N D9 gene was inserted in a pPicZα C empty vector by ligation 
independent cloning. Cloning success was confirmed by DNA sequencing. Also, the 
presence of the MAO-N gene was verified by subjecting the circular plasmid to two 
restriction enzymes, XhoI and BamHI, that selectively cut the gene in two segments of           
1872 bp and 3100 bp. Successful cleavage was verified by agarose gel electrophoresis 
(Figure 23). 
 
Figure 23. Agarose gel electrophoresis of MAO-N D9 in pPicZα C after action of the 
restriction enzymes XhoI and BamHI. 
The complete circular plasmid was linearized with a PmeI restriction enzyme for 
transformation into P. pastoris cells. Insertion of plasmid DNA in P. pastoris was achieved 
by electroporation. Unfortunately, transformation efficiencies for this organism are 
considerable lower than with E. coli as the plasmid needs not only to enter the cell but also 
be incorporated in the host’s genome. In order to achieve successful insertion, care must be 
taken with cell viability and concentration of DNA and cell in the electroporation cuvette. 
Moreover, cell growth with several concentrations of antibiotic is required for the selection 
of the best multi-copy recombinants, that is, multiple insertion of the gene in the host’s 
genome. 
Transformation of MAO-N into P. pastoris was attempted for five times before successful 
transformants were found. Even then, only two colonies grew on an YPD plate with            
1000 µg/ml Zeocin™. PCR of both colonies, with the previous primers from the ligation 
independent cloning, followed by agarose gel electrophoresis revealed the presence of a band 
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around 1.5 kb, corresponding to amplification of the MAO-N D9 gene (Figure 24). This 
confirmed a successful insertion of the target gene. Besides, the high intensity of the band 
suggests the insertion of multiple copies into the P. pastoris genome, therefore increasing 
the likelihood of high MAO-N D9 expression in future cell growth experiments. 
 
Figure 24. Agarose gel electrophoresis of the results from the Touchdown PCRs for the 
amplification of MAO-N D9 gene in P. pastoris’ genome. A) 1 kb DNA ladder; B) Unrelated 
run; C) Touchdown PCR with colony 1; D) Touchdown PCR with colony 2. 
3.2 SUBSTRATE SCOPE OF MAO-N IN THE OXIDATION OF 
TETRAHYDROISOQUINOLINES 
3.2.1 Overview 
A colorimetric specific activity assay was optimized to quickly determine the activity of 
MAO-N variants with THIQ substrates. MAO-N can catalyse the oxidation of primary and 
secondary amines to imines, producing hydrogen peroxide as a sub product. In the presence 
of HRP, H2O2 can catalyse the oxidative coupling of TBHBA with 4-AAP, producing a 
highly stable magenta dye (Scheme 20). Its concentration can be monitored measuring the 
absorbance at 510 nm. Moreover, when plotting absorbance vs time, a direct proportionality 
can be found between the slope of the graphic obtained and the specific activity of the 
enzyme. 
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Scheme 20. Oxidative coupling of TBHBA and 4-AAP 
Eleven different substrates were used in this analysis, as mentioned in Figure 16, and tested 
with the MAO-N variants found in Table 1. Besides the already reported MAO-N D5, D9 
and D11 mutants, eight mutants, selected from a library of single and double mutations on 
MAO-N D5 under development by Jane Kwok et al.115, were studied for the first time with 
THIQ substrates. The absorbance of all reactions was monitored over time, the specific 
activity calculated accordingly and the results presented in the following Figures 25 to 29. 
3.2.2 Specific activity assays 
The specific activity of MAO-N variants with α-AMBA (66) (see structure in Scheme 14) 
and THIQ (19) (see structure in Figure 16) is presented in Figure 25. α-AMBA was used 
as a positive control to confirm that the enzyme was expressed in its active conformation. 
As expected, all variants showed activity with this substrate. However, its similarity with the 
natural substrate of this enzyme seems to evidence that a greater change in the enzyme’s 
active site, as seen in MAO-N D11, can lead to a significant decrease in activity with simple 
substrates. 
Surprisingly, all MAO-N D12 variants had higher specific activities with THIQ than with  
α-AMBA, reaching a surprising 7-fold increase in activity for D12 (H). In fact, the new 
engineered mutants appeared to follow a different evolutionary route than the previously 
reported with MAO-N D9 and D11, maintaining and even improving MAO-N D5’s 
preference for unsubstituted THIQ over α-AMBA. 
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Figure 25. Specific activity of MAO-N variants with racemic α-AMBA – in blue – and 
THIQ – in grey. 
The procedure was repeated with MTQs. In Figure 26 and 27 it is possible to assess the 
influence of an increased steric hindrance near the amine group to the activity of all               
MAO-N variants. First, and as expected, MAO-N D9 showed significantly higher activity 
with this substrate than other mutants.  
 
Figure 26. Specific activity of MAO-N variants with 1-MTQ 
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Still, different results were found when comparing substitutions in the remaining positions 
of the pyrimidine ring, as these substrates were not easily accepted by any enzyme variant. 
First, and in contrast with MAO-N D9 and D11, the activity of MAO-N D12 variants with 
4-MTQ (86) (see structure in Figure 16) appeared to be much higher than with 3-MTQ (85) 
(see structure in Figure 16). Most importantly, MAO-N D12 mutants showed the highest 
activity so far reported for 4-MTQ, with an up to 17-fold improvement from MAO-N D5.  
 
Figure 27. Specific activity of MAO-N variants with 3-MTQ – in blue – and 4-MTQ – in 
grey. 
Next, the activity of MAO-N variants with THIQ with substituents in the aromatic ring was 
determined. Figure 28 shows that MAO-N D9 presented exceptional activity with 5,6 and 
8-MTQ - (87), (88) and (90), respectively (see structures in Figure 16). Nevertheless, the 
new MAO-N D12 mutants showed a significant increase in activity from MAO-N D5, up to 
16-fold. Consistent with the results is the higher acceptance by these new mutants of 5-MTQ, 
presenting a similar activity profile to MAO-N D5. Remarkably, some MAO-N D12 variants 
are now the most promising enzymes for the oxidation of these methylated THIQs. 
Finally, very low activities were found testing all MAO-N variants with 7-MTQ (89) (see 
structure in Figure 16), and only MAO-N D12 (C) and (G) showed any significant activity 
at 0.0051 and 0.027 U/mg, respectively. 
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Figure 28. Specific activity of MAO-N variants with 5-MTQ, in blue, 6-MTQ, in grey, and 
8-MTQ, in orange. 
It is known that MAO-N does not accept 6,7-dimethoxy substituents in its aromatic ring but 
no study as so far determined if mere steric hindrance is involved or a change in the 
electronic distribution of the molecule. Given the exceptional activity obtained from           
MAO-N D12 mutants with THIQs, in general, and particularly with 7-MTQ, the specific 
activity of all MAO-N variants with DMTHIQ (91) (see structure in Figure 16) and 1-M-
DMTHIQ (92) (see structure in Figure 16) was also determined and is presented in Figure 
29. 
All the enzymes tested showed very low activities with dimethoxylated substrates. 
Nevertheless, MAO-N D9, MAO-N D12 (C) and MAO-N D12 (G) had the highest activity 
of all variants with DMTHIQ. Remarkably, MAO-N D9 maintained its activity when tested 
with 1-M-DMTHIQ and MAO-N D12 (C) suffered only a slight decrease in activity. In 
contrast, MAO-N D12 (G) proved to be completely unable to oxidize this substrate. 
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Figure 29. Specific activity of some MAO-N variants with DMTHIQ, in blue, and                         
1-M-DMTHIQ, in grey. 
3.2.3 Final discussion 
In this section a specific activity assay was used to study the substrate scope of several 
engineered MAO-N variants with THIQ derivatives, with interesting results. A summary of 
the results aforementioned is presented in Figure 31. First, it seems clear that the substrate’s 
substitution pattern can have a huge influence in the enzyme’s activity (Figure 30). 
Although simple non-polar substitutions in the 5, 6 or 8 positions can maintain or even 
improve the activity of some MAO-N variants, substitutions in the 7 position do not seem to 
be accepted at all. Moreover, the four mutations present in MAO-N D9 and not in MAO-N 
D5, shown in Table 1, appear essential in the acceptance of small substituents in C1 by the 
enzyme. In fact, the low activity seen in MAO-N D11 with 1-MTQ, by comparison with 
MAO-N D9, indicates that the only different amino acid between these mutants, W430, may 
be responsible for this selective behaviour. 
Second, C3 and C4 substitutions can significantly hinder the enzyme’s activity, by either 
changing the electronic properties of the molecule, and subsequently altering the amine’s 
pKa, or making it difficult to accommodate the target molecule inside the active pocket. It 
is our belief that the increase in activity seen in some MAO-N D12 mutants supports the 
second hypothesis, as the change in the enzyme’s secondary structure, far from the aromatic 
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cage, is more likely to alter the shape or size of the active pocket and, therefore, its ability to 
accommodate larger substrates. 
 
Figure 30. Summary of the activity of MAO-N variants with methyl substituted THIQs, 
with the circles representing the carbons in which the methyl group was added. Green -high 
activity with most tested variants; orange – average activity with most tested variants; red – 
very low activity with all tested variants; blue – high activity only with MAO-N D9. 
Finally, the results showed remarkable activities for MAO-N D12 (C) and D12 (G) with 
dimethoxylated substrates, similar or even higher than the activity here reported with             
MAO-N D9. Nevertheless, while MAO-N D12 (C) maintained its activity with                                 
1-M-DMTHIQ, the (G) variant was completely inactive with this substrate. What’s more, 
this behaviour was comparable to the one seen in 1-MTQ, where this last variant showed 
complete loss in activity by the addition of a 1-methyl substitution. This suggests an inability 
by the enzyme to accept C1 substitutions, therefore limiting its substrate scope. As so and as 
previously stated, the increase in the size of the active pocket caused by the mutations present 
in MAO-N D9, especially in the W430 residue, can be essential for the accommodation of 
C1 substituted THIQ’s in the active site. 
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Figure 31. Summary of the mutants with best activity towards each one of the substrates 
tested. The values presented are relative to the best activity determined for α-AMBA            
(MAO-N D9) 
 
3.3 DIRECTED EVOLUTION OF MAO-N D9 BY SITE-DIRECTED 
MUTAGENESIS 
3.3.1 Overview 
The MAO-N D12 (G) mutant presented remarkable activity towards DMTHIQ, the highest 
activity ever reported by a MAO-N variant. Unfortunately, this mutant seems to lose all 
activity by the presence of a substitution in C1. On the other hand, MAO-N D9 presented 
similar activities with both substrates, easily accommodating the additional methyl group. 
Following the principle of additivity, explained in Chapter 1, we set out to see if the addition 
of the two additional mutations in MAO-N D12 (G) – S205T S206N – to MAO-N D9 could 
generate a new enzyme with increased activity towards 1-M-DMTHIQ. 
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3.3.2 Oxidation and deracemization of salsolidine 
The double point mutation was performed by both GC and HF PCR with designed mutagenic 
primers and success confirmed by sequencing of overnight cultures in NEB® 5-alpha. For 
the purposes of this work the new mutant was named MAO-N D13. 
MAO-N D13 was expressed in E. coli BL21(DE3) but purification did not yield any 
significant amount of protein. As so, specific activity assays couldn’t be performed with the 
new mutant. Nevertheless, biotransformations were set to verify the enzyme’s ability to 
oxidise (rac)-1M-DMTHIQ (92) to 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline (96) 
and the results analysed by HPLC (Scheme 21). The relative response factor was 2.82, 
calculated as described in the experimental section. 
 
Scheme 21. Oxidation of 1-M-DMTHIQ with MAO-N variants 
MAO-N D9 was used as a negative control. A whole-cell biotransformation was set using 
MAO-N D9 in E. coli BL21(DE3) and its results presented in Figure 32. Only 0.92% yield 
was found after 4 days, confirming previous results that this mutant could not catalyse the 
aforementioned reaction. On the other hand, the new MAO-N D13 mutant achieved a 
remarkable yield of 29.8% in the same time period, showing an over 30-fold increase in 
activity. Amazingly, it appears to be the first ever recorded successful biotransformation of 
dimethoxylated tetrahydroisoquinolines with a MAO-N variant.  
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Figure 32. Normal phase HPLC trace (CHIRACEL® OD-H 250 mm x 4.6 mm, 5 µm, eluent: 
hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 280 nm) of three 
biotransformations: oxidation of (92) with MAO-N D9 (top), oxidation of (92) with  
MAO-N D13 (middle) and deracemisation of (92) with MAO-N D13 (bottom). RT[(S)-amine] 
= 21.79 min*; RT[(R)-amine] = 28.89 min* ; RT[imine] = 14.65 min. 
*Enantiomer peaks identified according to the literature.94 
Moreover, analysis of the remaining amine peaks showed a 49.5% enantiomeric excess of 
the (R) enantiomer (97), with no significant decrease in its peak area (by comparison with a 
10mM racemic standard), indicating MAO-N D13 to be very selective towards  
(S)-1-M-DMTHIQ (98). As so, the reaction yield could be calculated by the conversion of 
(98) to (96), estimated at approximately 60%. These results showed that MAO-N D13 could, 
in theory, be used for the kinetic resolution of racemic 1-M-DMTHIQ due to its high activity 
and selectivity towards one enantiomer. 
In light of these results, the dynamic kinetic resolution of 1-M-DMTHIQ with MAO-N D13 
and NH3
.BH3 was attempted. Unfortunately, no significant change in enantiomer 
concentration was found over a 4-day reaction period. The reaction rate appears too small to 
ensure enough cycles of oxidation-reduction in a reasonable time period. No further 
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reactions were attempted, but an increase in enzyme loading could, in theory, lead to better 
results. Nevertheless, the identification of a new MAO-N mutant with increased activity is 
still remarkable and can stand as a starting point for further directed evolution experiments 
targeting dimethoxylated substrates. 
3.4 DYNAMIC KINETIC RESOLUTION OF CHIRAL 
TETRAHYDROISOQUINOLINES 
3.4.1 Overview 
Pure chiral amines are increasingly common in the pharmaceutical industry, driving a 
constant search for new and sustainable methods towards their synthesis or resolution. In 
this section, four enzymes - MAO-N D5, D9, D11 and HDNO - were investigated for their 
ability to oxidase several chiral amines. 
DKR of chiral amines with MAO-N variants has been previously described in Chapter 1. It 
has remarkable advantages to common resolution methods, as it can reach 100% yield and 
have a low environmental impact. In this work, HDNO and an appropriate MAO-N variant, 
according to the literature, were used for the deracemisation of α-AMBA and several 
tetrahydroisoquinolines, as follows. 
3.4.2 Resolution of chiral amines 
3.4.2.1 α-Methylbenzylamine 
The deracemisation of α-AMBA with MAO-N D5 has been previously reported with great 
success, as stated in Chapter 1. In this work, both MAO-N D5 and HDNO were used in this 
reaction (Scheme 22) and, surprisingly, appear to have reverse selectivity. With MAO-N 
D5, an e.e. of 74% of the (R) enantiomer (68) was reached within 2 hours, and complete 
deracemization should shortly follow (Figure 33). Contrarily, an e.e. of only 16% of  
(S)-α-AMBA (99) was obtained with HDNO after two days, proving that, although selective 
towards this isomer, this enzyme is not very active. 
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Scheme 22. Deracemisation of α-AMBA with MAO-N D5 and HDNO 
 
Figure 33. Normal phase HPLC trace (CHIRACEL® OD-H 250 mm x 4.6 mm, 5 µm, eluent: 
hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of the deracemisation of 
α-AMBA with HDNO (top) or MAO-N D5 (bottom). RT[(R)-amine] = 8.77 min;  
RT[(S)-amine] = 10.67 min. 
 
3.4.2.2 1-Methyltetrahydroisoquinoline 
A similar procedure was used for 1-MTQ (Scheme 23) and the HPLC results shown in 
Figure 34. MAO-N D9 was the monoamine oxidase variant used in this experiment due to 
its high activity with this substrate, previously reported in Chapter 3. Full conversion to 
(R)-MTQ (71) was found with MAO-N D9 after two hours, while with HDNO only 29.9% 
Chapter 3. results and discussion 
 
70 
 
e.e. of (S)-MTQ (100) was attained after 2 days. Even so, this result presents an increase in 
activity for HDNO, by comparison with α-AMBA. 
 
Scheme 23. Deracemisation of 1-MTQ with MAO-N D9 and HDNO 
 
Figure 34. Normal phase HPLC trace (CHIRACEL® OD-H 250 mm x 4.6 mm, 5 µm, eluent: 
hexane/isopropanol/diethylamine = 98/2/0.1, 1 mL/min, 254 nm) of the deracemisation of 
1-MTQ with HDNO (top) or MAO-N D9 (bottom). RT[(S)-amine] = 12.13 min; RT[(R)-amine] = 
12.68 min. 
*Enantiomer peaks identified by comparison with known literature.103 
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3.4.2.3 Crispine A 
Finally, the deracemization of Crispine A, a known antitumor drug, was attempted with 
HDNO and MAO-N D11 (Scheme 24). Unfortunately, only 15.8% e.e. of (R)-Crispine (77) 
was found after 2 days (Figure 35). Also, HDNO proved to be either inactive or non-
selective towards this substrate. Nevertheless, the low activity of MAO-N D11 with Crispine 
A could be justified by the increased difficulty in the oxidation of tertiary amines, as no 
mention of catalytic loading was made in previous articles. 
 
 
Scheme 24. Deracemisation of Crispine A with MAO-N D11 and HDNO 
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Figure 35. Normal phase HPLC trace (CHIRACEL® OD-H 250 mm x 4.6 mm, 5 µm, eluent: 
hexane/isopropanol/diethylamine = 90/10/0.1 (top) or 95/5/0.1 (bottom), 1 mL/min, 254 nm) 
of the deracemisation of Crispine A with HDNO (top) or MAO-N D11 (bottom). RT[(S)-amine] 
= 12.13 min; RT[(R)-amine] = 12.68 min. 
*Enantiomer peaks identified by comparison with known literature.94  
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3.5 ONE POT THREE STEP CASCADE FOR THE C1 FUNCTIONALIZATION 
OF TETRAHYDROISOQUINOLINES 
3.5.1 Overview 
Functionalized THIQs can act as precursors to important alkaloids with known 
pharmacological applications. In this work, a one-pot three step cascade reaction was 
devised to synthetize tetrahydroisoquinoline-1-carboxylic acids (106) (Scheme 25). First, 
MAO-N D9, D12 (G) or HDNO were used in the conversion of several THIQs (103 a-e) to 
the corresponding 3,4-dihydroisoquinoline analogues (104 a-e), as described in Chapter 2. 
These were treated with potassium cyanide in an acid environment to yield                                          
1-cyanotetrahydroisoquinolines (105 a-d). The cyano compounds were then selectively 
hydrolysed by commercial nitrilases, and both the conversion and enantiomeric excess 
determined by reverse-phase HPLC. 
 
 
Scheme 25. Cascade reaction for the stereoselective synthesis of  
tetrahydroisoquinoline-1-carboxylic acids. Compound (19) was renumbered to (103a) to 
allow a better comprehension of the following results by the reader. 
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3.5.2 Synthesis of 3,4-dihydroisoquinolines 
3.5.2.1 Overview 
MAO-N D9, D12 (G) or HDNO were used in the oxidation of several THIQs. First, small 
biotransformations were set and analysed by HPLC. When near full conversion was reached 
within 48 hours, the biotransformations were replicated in a larger scale and analysed by 
1H NMR, as presented. The obtained 3,4-dihydroisoquinolines (104 a-e), confirmed by 
1H NMR, were used in the determination of response factors, and the final yield was 
calculated from the previous small scale HPLC runs. An exception is made for  
3,4-dihydroisoquinoline (104a) as the commercial imine standard was available. 
The 1H NMR spectrum of 5-methyl-3,4-dihydroisoquinoline as a direct result of the 
oxidation of 5-MTQ by MAO-N D9 is shown in Figure 36 as an example. First, the H-1 
peak can be seen at 8.25 ppm in the form of a triplet, coupling at long distance with the H-3 
protons. It suffers the inductive deshielding effect of the highly electronegative nitrogen 
atom, as well as the anisotropic deshielding effect caused by the C1=N double bond 
conjugated with the aromatic ring. 
Next, the signals correspondent to the three aromatic protons can be seen between 7.05 and 
7.20 ppm, all suffering the anisotropic effect of the aromatic ring. The signal from the H-8 
proton appears as a doublet, coupling with H-7, at a higher chemical shift due to the increased 
anisotropic effect from the C1=N bond and the inductive effect of the nitrogen atom. At  
7.14 ppm appears the H-7 signal as a triplet, by coupling of this proton with H-6 and H-8. 
Finally, the signal of H-6 appears at 7.07 ppm as a doublet, coupling with H-7. 
The signals from the aliphatic protons appear last in the 1H NMR spectrum, with H-3 and 
H-4 signals presenting an downfield shift due to their proximity to the heteroatom and the 
aromatic ring. In fact, the direct bond to the nitrogen atom causes a downfield shift of the  
H-3 signal (3.72 ppm) that appears as a double triplet by coupling with H-1 and the H-3 
protons.  Next, the signal from H-4 appears as a triplet at 2.62 ppm, coupling only with  
H-3. Finally, the H-9 protons’ signal from the methyl group appears as a singlet at 2.22 ppm, 
suffering only slightly the anisotropic effect of the aromatic ring. 
6-MTQ and 8-MTQ present similar 1H NMR spectra, with some slight differences in the 
chemical shift of the signals correspondent to the aromatic protons. Nevertheless, these 
signals were easily assigned by their multiplicity. On the other hand, the spectrum of  
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6,7-dimethoxy-3,4-dihydroisoquinoline shows significant differences due to the addition of 
electronegative atoms. First, the signals of the methyl protons adjacent to an oxygen atom 
appear as singlets at 3.83 and 3.85 ppm, suffering its deprotective inductive effect. Then, the 
aromatic protons’ (H-5 and H-8) signal present a downfield shift due to its ortho position to 
the methoxy groups, suffering an important resonance deprotecting effect. 
 
Figure 36. 1H NMR spectrum of 5-methyl-3,4-dihydroisoquinoline as a direct result of an 
oxidation by MAO-N D9  
 
3.5.2.2 3,4-Dihydroisoquinoline 
The oxidation of THIQ (103a) with MAO-N D9 or HDNO was monitored over a 48-hour 
period. A yield over 99% was reached with MAO-N D9, as shown in Figure 37. On the 
other hand, a reduced yield of 50.1% was determined for HDNO in this time period. 
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Figure 37. Normal phase HPLC trace (CHIRAPACK® IC™ 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of the oxidation of 
(103a) with HDNO (top) and MAO-N D9 (bottom). RT[amine]= 15.03 min; RT[imine]= 20.14 
min. 
3.5.2.3 5-Methyl-3,4-dihydroisoquinoline 
MAO-N D9 was used in the synthesis of 5-methyl-3,4-dihydroisoquinoline (104e) with 
>99% yield after 2 days, as reported in Figure 38. Oxidation with HDNO was also attempted 
but resulted only in a 23.3% yield.  
 
 1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.22 (s, 3H, H-
9); 2.62 (t, 2H, J 7.8 Hz, H-4); 3.72 (dt, 2H, J 7.8 and 2.0 Hz, 
H-3); 7.07 (d, 1H, J 7.3 Hz, H-6); 7.14 (t, 1H, J 7.3 Hz, H-7); 
7.18 (d, 1H, J 8.2 Hz, H-8); 8.25 (t, 1H, J 2.0 Hz, H-1). 
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Figure 38. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of the oxidation of 
(103e) with HDNO (top) and MAO-N D9 (bottom). RT[amine]= 12.01 min; RT[imine]= 9.51 
min. 
 
3.5.2.4 6-Methyl-3,4-dihydroisoquinoline 
MAO-N D9 successfully oxidised 6-MTQ (103b) with >90% yield in two days, as seen in 
Figure 39. This result is compatible with the high specific activity presented by this variant 
in the colorimetric assay. Moreover, HDNO also showed full conversion in this time interval. 
Still, an unknown compound in high concentration was detected by a peak at 10.4 min in the 
final HPLC, along with a decrease in the expected imine signal (7.49 min). The presence of 
an additional enzyme, expressed by the cell and capable of reacting with either the substrate 
or the product and thus generate a new compound, can explain this phenomenon. Also, but 
less likely, the unprompted oxidation of the imine (104b) to  
6-methyl-3,4-dihydroisoquinolin-1(2H)-one may have occurred. 
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.30 (s, 3H, 
H-9); 2.65 (t, 2H, J 7.8 Hz, H-4); 3.66-3.70 (m, 2H, H-3); 
6.91 (s, 1H, H-5); 7.03 (d, 1H, J 7.6 Hz, H-7); 7.11 (d, 1H, 
J 7.6 Hz, H-8); 8.24 (t, 1H, J 2.0 Hz, H-1). 
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Figure 39. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of the oxidation of 
(103b) with HDNO (top) and MAO-N D9 (bottom). RT[amine]= 8.34 min; RT[imine]= 7.49 
min. 
 
3.5.2.5 8-Methyl-3,4-dihydroisoquinoline 
Unsurprisingly, > 99 % yield was obtained in the oxidation of 8-MTQ (103c) with MAO-N 
D9. HDNO was also suitable for this reaction as a yield of 87% was achieved after only two 
days. The HPLC traces of both reactions can be seen in Figure 40. 
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.41 (s, 3H, H-
9); 2.64 (t, 2H, J 7.7 Hz, H-4); 3.62-3.67 (m, 2H, H-3); 6.92 
(s, 1H, J 7.4 Hz, H-5); 7.01 (d, 1H, J 7.4 Hz, H-7); 7.17 (t, 
1H, J 7.4 Hz, H-6); 8.57 (t, 1H, J 2.0 Hz, H-1). 
 
Chapter 3. results and discussion 
 
79 
 
 
Figure 40. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of the oxidation of 
(103c) with HDNO (top) and MAO-N D9 (bottom). RT[amine]= 11.36 min; RT[imine]= 10.48 
min. 
3.5.2.6 6,7-Dimethoxy-3,4-dihydroisoquinoline 
The oxidation of DMTHIQ (103d) with MAO-N D12 (G) and HDNO was attempted with 
limited success. Oddly, a shift was found in the substrate HPLC peak’s location between the 
standard (~20 min) and the biotransformation runs (~27 min), preventing a correct 
calculation of the relative response factor. Nevertheless, the area of the imine (104d) peak 
in Figure 41 – (top), related to the HDNO biotransformation, is consistent to the product 
peak areas in previous experiments (~80000). Moreover, previous articles report full 
conversion of this substrate with HDNO. As so, this value was associated to full conversion 
to the imine, and yield in the MAO-N D12 (G) biotransformation calculated accordingly – 
31.0 %. We highlight these values may not be accurate and must be used as reference with 
caution. 
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.61 (t, 
2H, J 7.5 Hz, H-4); 3.64-3.69 (m, 2H, H-3); 3.83 (s, 
1H, OCH3); 3.85 (s, 1H, OCH3); 6.60 (s, 1H, H-5); 
6.74 (s, 1H, H-8); 8.16 (t, 1H, J 2.0 Hz, H-1). 
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Figure 41. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 90/10/0.1, 1 mL/min, 254 nm) of the oxidation 
of (103d) with HDNO (top) and MAO-N D12 (G) (bottom). RT[amine]= 27.23 min; 
RT[imine]= 12.73 min. 
 
3.5.3 Synthesis of 1-cyanotetrahydroisoquinolines 
1-Cyanotetrahydroisoquinolines (105 a-d) were synthetized from the corresponding imines 
(104 a-d) by the addition of cyanide in acid medium, according to the mechanism presented 
in Scheme 26. The previously reported imines from large scale biotransformations were 
extracted and used directly. 1H NMR analysis was used to determine the yield of the 
synthesis of (104) and (105) compounds, as shown in the following example. 
 
Scheme 26. Mechanism for the cyanation of 3,4-dihydroisoquinoline with cyanide 
Figure 42 shows the 1H NMR spectrum of the reaction product from the cyanation of  
3,4-dihydroisoquinoline. It is possible to see two very distinct signals whose ratio allowed 
an easy and accurate determination of the yield. The signal (A), corresponding to the H-1 
proton from 3,4-dihydroisoquinoline, is present as a triplet at 8.26 ppm, as previously 
reported, while the signal corresponding to the same proton in  
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1-cyanotetrahydroisoquinoline appears as a singlet 4.96 ppm. Though suffering the 
deshielding inductive effect of the CN triple bond and nitrogen atom and the anisotropic 
effect of the aromatic ring, this proton did not suffer the previous anisotropic effect of the 
conjugated double bond, thus suffering a downfield shift. The presence of the equivalent 
THIQ (103), present due to an incomplete oxidation in the first step, can also be detected in 
some of the spectra by the presence of a singlet peak around 3.8 ppm, corresponding to the 
H-1 protons. 
Additional characteristic 1-cyanotetrahydroisoquinoline signals could be found in the 
spectrum. First, the presence of a multiplet signal corresponding to the four aromatic protons, 
indistinguishable due to the lack of additional effects besides the anisotropic effect of the 
aromatic ring. Then, the presence of a very characteristic ABXY system constituted by the 
H-3 (AB) and H-4 (XY) protons, leading to three distinct NMR signals: an AB system at 3.2 
ppm, in the form of a multiplet, and formed by the signals of the H-3 protons; a doublet of 
doublet of doublets signal (ddd) formed by the coupling of the HA-4 proton with HB-4 and 
both H-3 protons with different coupling constants; and a doublet of triplets (dt) formed by 
the coupling of the remaining HB-4 proton with HA-4 and with the two H-3 protons, in this 
case with similar coupling constants. An interesting phenomenon is therefore observed, as 
the orientation of the H-4 protons is not symmetrical and only one of them couples equally 
with both H-3 protons. Moreover, it could be verified that in most cases the central peaks of 
the ddd signal collapsed to form a larger central peak. Finally, the existence of a wide peak 
at 2.12 ppm, corresponding to the N-H proton, was also found in most spectra. 
Important differences can be found in an additional 1H NMR spectra of methylated  
1-cyanotetrahydroisoquinolines. First, the methyl groups can be identified by a singlet signal 
around 2.25 ppm. Then, the signals corresponding to the aromatic protons can be assigned, 
with the H-5 and H-7 protons appearing more protected and the H-6 and H-8 protons more 
deshielded. Finally, in the spectra of 6,7-dimethoxy-1-cyanotetrahydroisoquinoline, the 
signals corresponding to the methyl groups appears at 3.79 and 3.80 ppm, due to inductive 
effect of the oxygen atom, and the signals from the aromatic protons suffer a significant 
upfield effect, due to the resonance effect of their ortho position to the methoxy groups. 
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Figure 42. 1H NMR of the product from the cyanation of 3,4-dihydroisoquinoline 
Figure 43 further shows the 13C NMR spectrum of the same reaction and can serve as an 
example for the signal identification of 1-cyanotetrahydroisoquinolines. First, signals in the 
aliphatic area could be found at 28.23, 40.76 and 48.35 ppm, correspondent to the C-4, C-3 
and C-1, respectively. An downfield shift was found in the last two carbons due to the 
inductive deshielding effect of the proximity to an electronegative atom (NH) and the 
inductive effect in C-1 of the proximity to a CN group. Next, the signal corresponding to the 
CN carbon can be seen at 120.2 ppm, suffering an downfield shift by its different 
hybridization (sp) and the inductive effect of the nitrogen atom. Finally, the six signals 
corresponding to the aromatic carbon can be found between 125 and 135 ppm. First, the four 
CH signals could not be identified, appearing between 126 and 130 ppm. Then, the two 
quaternary carbon signals, C-4a and C-8a, were identified at a higher chemical shift (129.42 
and 134.71 ppm) due to the inductive effect of an additional C-C bond. The C-8a signal 
appears at a higher chemical shift due to the additional inductive effect of the proximity to 
the nitrogen atom. 
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Some differences can also be found in the 13C NMR spectrum of the nitriles synthetized. 
First, the signal corresponding to the methyl carbon appears with the lowest chemical shift, 
suffering only slightly the inductive effect of the ring. Then, the additional quaternary carbon 
formed by the presence of a methyl group suffers a downfield effect due to the additional  
C-C bond, in the range of 10 ppm. Major changes to this spectrum are seen with (105d) 
(Scheme 21). First, the signals corresponding to the CH carbons appear at a lower chemical 
shift, with C-8 suffering the additional inductive effect of the proximity to the cyano group 
and nitrogen atom. Then, a similar shift is found with the quaternary carbons C-4a and  
C-8a, whose signal appears at 120.99 and 126.95 ppm. Last, the signals corresponding to the 
C-6 and C-7 quaternary carbons suffer the highest downfield effect due to the additional 
inductive effect of the oxygen atom, appearing at 147.87 and 149.17 ppm. 
Figure 43. 13C NMR of the product from the cyanation of 3,4-dihydroisoquinoline 
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3.5.3.1 1-Cyanotetrahydroisoquinoline 
 
1-Cyanotetrahydroisoquinoline (105a) was synthesized from 
commercial 3,4-dihydroisoquinoline (104a) with 91.7 % yield. 
 
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.10 (s, 1H, NH); 2.70 (dt, 1H, J 16.6 and 3.6 
Hz, H-4); 2.86 (ddd, 1H, J 16.5, 10.1 and 6.3 Hz, H-4); 3.13 - 3.23 (m, 2H, H-3); 4.96 (s, 
1H, H-1); 7.05 – 7.20 (m, 4H, H-5/H-6/H-7/H-8). 
13C NMR (100.6, CDCl3): δ (ppm) = 28.23 (C-4); 40.76 (C-3); 48.35 (C-1); 120.20 (CN); 
126.59, 127.10, 128.45 and 129.90 (C-5, C-6, C-7 and C-8); 129.42 (C-4a); 134.71 (C-8a). 
 
3.5.3.2 1-Cyano-6-methyltetrahydroisoquinoline 
 
1-Cyano-6-methyltetrahydroisoquinoline (105b) was synthesized 
from 6-methy-3,4-dihydroisoquinoline (104b) with 82.6 % yield. 
Yield of the two-step synthesis of the cyano compound from  
6-MTQ was 70.7 %.  
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.25 (s, 3H, H-9); 2.66-2.72 (m, 1H, H-4); 2.83 
(ddd, 1H, J 16.4, 10.1 and 6.3 Hz, H-4); 3.14 - 3.25 (m, 2H, H-3); 4.94 (s, 1H, H-1); 6.90 (s, 
1H, H-5); 6.96 (d, 1H, J 7.9 Hz, H-7); 7.04 (d, 1H, J 7.9 Hz, H-8). 
13C NMR (100.6 MHz, CDCl3): δ (ppm) = 21.13 (C-9); 28.22 (C-4); 40.81 (C-3); 48.15 (C-
1); 120.29 (CN); 126.94, 127.46, 130.34 (C-5, C-7 and C-8); 129.82 (C-4a); 134.42 (C-8a); 
138.27 (C-6). 
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3.5.3.3 1-Cyano-8-methyltetrahydroisoquinoline 
 
1-Cyano-8-methyltetrahydroisoquinoline (105c) was synthesized from 
8-methyl-3,4-dihydroisoquinoline (104c) with 99.2 % yield. Yield of 
(102c) from 8-MTQ was 56.3 %. 
 
1H NMR (400.13 MHz, CDCl3): δ (ppm) = 2.28 (s, 3H, H-9); 2.68 (dt, 1H, J 16.6 and 2.7 
Hz, H-4); 2.93 (m, 1H, H-4); 3.19 – 3.24 (m, 2H, H-3); 4.92 (s, 1H, H-1); 6.86 – 7.00 (m, 
2H, H-5, H-7); 7.10 (t, 1H, J 7.6 Hz, H-6). 
13C NMR (100.6 MHz, CDCl3): δ (ppm) = 18.54 (C-9); 28.52 (C-4); 40.31 (C-3); 46.43  
(C-1); 119.39 (CN); 127.70, 128.27 and 128.37 (C-5, C-6 and C-7); 127.93 (C-4a); 134.67 
and 135.14 (C-8 and C-8a). 
 
3.5.3.4 1-Cyano-6,7-dimethoxytetrahydroisoquinoline 
 
1-Cyano-6,7-dimethoxytetrahydroisoquinoline (105d) was 
synthesized from 6,7-dimethoxy-3,4-dihydroisoquinoline (104d) 
with 71.9 % yield. Accumulated yield for the synthesis of (105d) 
from DMTHIQ was 62.3 %. 
 
1H NMR (400 MHz, CDCl3): δ (ppm) = 2.61 (dt, 1H, J 16.4 and 3.6 Hz, H-4); 2.80 (ddd, 
1H, J 16.4, 9.6 and 6.8 Hz, H-4); 3.16– 3.21 (m, 2H, H-3); 3.79 (s, 1H, OCH3); 3.80 (s, 1H, 
OCH3); 4.90 (s, 1H, H-1); 6.54 (s, 1H, H-5); 6.60 (s, 1H, H-8). 
13C NMR (100.6 MHz, CDCl3): δ (ppm) = 27.84 (C-4); 40.82 (C-3); 48.07 (C-1); 55.92 
(OCH3); 56.06 (OCH3); 109.36 (C-5); 111.97 (C-8); 120.29 (CN); 120.99 (C-4a); 126.96 
(C-8a); 147.87 and 149.17 (C-6 and C-7). 
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3.5.4 Nitrilase in the enantioselective hydrolysis of  
1-cyanotetrahydroisoquinoline 
To this moment, only 1-cyanotetrahydroisoquinoline was used in the nitrilase catalysed 
hydrolysis to tetrahydroisoquinoline-1-carboxylic acid (Scheme 27), according to the 
biotransformation described in Chapter 2. This substrate was used as is from previous 
experiments. The reaction was monitored by reverse-phase HPLC, showing loss of enzyme 
activity after 72 h. As so, more enzyme was added and the reaction monitored for an 
additional 48 h, leading to a total reaction time of 5 days. 
 
Scheme 27. Stereoselective hydrolysis of (105a) with nitrilases for the synthesis of 
tetrahydroisoquinoline-1-carboxylic acid. 
Yield in the synthesis of (106a) was determined by reverse-phase HPLC with a non-chiral 
column. A calibration curve was made with standard solutions of commercially available 
racemic product, as presented in Annex 1. Six different nitrilases from Prozomix® - N004, 
N006, N010, N014, N018, N020 – were tested for this reaction. Unfortunately, only N006 
showed significant activity, with a yield of 12.6 % calculated by comparing the carboxylic 
acid’s peak area in Figure 44 with the calibration curve mentioned. 
 
Figure 44. Reverse phase HPLC trace (ZORBAX Extend-C18 column 50 mm x 4.6 mm x 
3.5 µm, eluent: NH4OH 0.1 M pH=10/ methanol isocratic 90:10 (5 min), gradient from 90:10 
to 10:90 (over 15 min), isocratic 10:90 (10 min), 1 mL/min, 40ºC, 210 nm) of the 
biotransformation of unpurified (105a) with nitrilase N006. RT[acid]= 3.35 min;  
RT[imine]= 12.85 min; RT[cyano]= 12.99 min.  
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Next, the samples were run on a reverse-phase HPLC equipped with a chiral column, as 
shown in Figure 45. An enantiomeric excess of 88 % was found in the final run, evidencing 
the high selectivity of this nitrilase towards 105a. However, only the racemic standard was 
available and, therefore, it is impossible to determine to which enantiomer is this enzyme 
selective. 
 
Figure 45. Reverse-phase chiral HPLC trace (Chirobiotic T column 250 mm x 46 mm x 5 
µm, eluent: water/ methanol = 60/40/, 0.8 mL/min, 40ºC, 210 nm) of a 
tetrahydroisoquinoline-1-carboxylic acid 10mM standard (top) and the biotransformation of 
(105a) with nitrilase N006 (bottom). A and B identify the (106a) enantiomer peaks.  
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3.5.5 General discussion 
A proof of concept was presented for the enantioselective green synthesis of 
tetrahydroisoquinoline-1-carboxylic acids from commercially available THIQs. For this 
synthesis, a one-pot three-step route was envisioned and applied to a range of substituted 
THIQ’s. A summary the results can be found in Table 9. 
 
Table 9. Summary table for the results described in section 3.5. 
*Accumulated yield from (103) 
Substrate Imine (104 a-e) * Nitrile (105 a-d) * Acid (106a) * 
 
(103a) 
>99% MAO-N D9 
50.1% HDNO 
91.7% 
12.6% 
(88% e.e.) 
 
(103b) 
>90% MAO-N D9 
>99% HDNO 
(conversion) 
70.7% - 
 
(103c) 
>99% MAO-N D9 
86.7% HDNO 
56.3% - 
 
(103d) 
31.0% MAO-N D12 (G) 
>99% HDNO 
62.3% - 
 
(103e) 
>99% MAO-N D9 
23.3% HDNO 
- - 
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Results clearly show that MAO-N D9 promptly catalyses the oxidation of unsubstituted and 
5, 6 or 8-methyl THIQs with excellent yields. However, 3, 4 and 7 substitutions are still not 
tolerated by this variant. These results appear consistent to the specific activity assays and 
further attest the limited substrate scope of MAO-N. Nevertheless, HDNO proved to be a 
great alternative in the oxidation of dimethoxylated THIQ, increasing the range of 
tetrahydroisoquinoline alkaloids covered by this method. Sadly, scale-up considerably 
lowered the conversion, limiting the future steps of this synthetic route. 
All synthetized 3,4-dihydroisoquinolines were used in a cyanation reaction for the synthesis 
of 1-cyano compounds. Although good conversion was observed with all substrates, with a 
two-step overall yield over 57%, experiments showed that a slightly basic pH is required for 
the reaction to occur. Moreover, it is hypothesized that further studies in the scale-up of the 
enzymatic oxidation and further optimization of the cyanation procedure can potentially lead 
to overall yields over 90%. 
Finally, 1-cyanotetrahydroisoquinoline was chosen to study its selective hydrolysis with six 
commercial nitrilases by Prozomix®. From those, only the N006 variant showed any 
significant activity with this substrate, reaching 12.6% yield with a remarkable e.e. of 88%. 
The great selectivity of this enzyme does limit the yield to a maximum of 50%, therefore 
raising the theoretical yield to around 25%. Moreover, we conjecture that a more regular 
addition of new enzyme to the reaction could increase the final yield, as results have shown 
that the enzyme lost all activity after 72 h. Nevertheless, the yield obtained must be 
thoroughly analysed, as a green synthetic route towards these high value compounds, using 
cheap and available reagents and performed in water at low temperatures had not been 
previously reported. In fact, a 100-fold price valorisation can be found between the 
commercial amine and the racemic acid synthetized. 
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In this work, the potential of biocatalysis in the synthesis of chiral amines with industrial 
and pharmacological applications was explored. In particular, monoamine oxidase variants 
from Aspergillus niger were used in the deracemisation and functionalization of 
tetrahydroisoquinolines. Also, the substrate scope of MAO-N variants with these substrates 
was studied and its results used in the design of a new mutant for the deracemisation of 
salsolidine. 
It was determined that substitutions in the various positions of THIQ can seriously hinder or 
improve the activity of MAO-N variants. From these results a new mutant (MAO-N D13) 
was developed and proved effective in the oxidation of salsolidine. Unfortunately, DKR of 
this substrate could not be accomplished. Next, MAO-N variants and HDNO were used in 
the successful deracemisation of α-AMBA and several THIQ derivatives.  
Finally, a proof of concept is presented for the highly enantioselective one-pot three-step 
synthesis of tetrahydroisoquinoline-1-carboxylic acid from its C1 unsubstituted analogue. It 
is shown that this new cascade reaction can also potentially be applied to aromatic 
substituted THIQs. In fact, the production of a highly valuable chiral compound from a 
simple and easily obtainable derivative from petroleum can prove of great assistance in 
future industrial applications, placing a versatile functional group and therefore increasing 
its potential use as templates in the synthesis of tetrahydroisoquinoline alkaloids. More 
important, the synthesis of 1-carboxylic acid derivatives has only been briefly reported in 
the literature, and the pharmacological potential of this novel and complex α-amino acids 
remains to be explored. 
Nevertheless, the work performed during this master thesis stands only as a starting point in 
new potential routes for the development of MAO-N in biocatalysis. First, the expression of 
MAO-N D9 in the newly obtained Pichia pastoris cells must be finished to determine its 
ability to express large quantities of protein. If successful, this method can be used to express 
other variants and eventually substitute E. coli as the chosen organism for a relatively fast 
expression of great amounts of MAO-N. 
Moreover, the search for MAO-N variants with diverse substrate scopes should continue, as 
shown in the remarkable results of the substrate screening. As an example, new variants with 
increased activity for 3-MTQ and 4-MTQ could prove effective in the oxidation of these 
substrates. Also, additional mutations to MAO-N D13, possibly from the mutations in the 
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MAO-N D12 mutants, could finally lead to a successful and fast deracemisation of 
salsolidine.  
Considerable work is still required in the optimization of the enzymatic cascade shown 
above. Additional experiments could overcome the decrease in conversion verified in the 
scale-up of the amine oxidation, and optimization of the optimal pH conditions for the 
cyanation is still required. Moreover, the development of a protocol that does not require 
product extraction would prove advantageous in future applications, saving both time and 
solvents. Also, in a non-extracting protocol the use of a stoichiometric amount of cyanide 
would be preferential to avoid enzyme poisoning in the last step. Last, to increase the overall 
yield new nitrilases could be acquired and tested for its ability to selectively hydrolyse these 
cyano compounds. 
In a wider perspective, investigation of the applicability of this new synthetic route to 
different substrates could lead to an increasingly used method to chiral amino acids. Also, 
the discovery of new mutants with unreported and exciting new characteristics can stimulate 
new applications for these enzymes. Most importantly, the development, in this work, of 
new segments for future exploration can hopefully encourage the scientific community to 
re-orient its investigation back to this overlooked high-potential monoamine oxidase. 
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1.1.1.  ANNEX 1. CALIBRATION CURVES 
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Figure A1.1. Calibration curve for the determination of protein concentration. 
 
 
Figure A1.2. Calibration curve for the reverse-phase HPLC run of tetrahydroisoquinoline-
1-carboxylic acid 
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ANNEX 2. SPECIFIC ACTIVITY 
ASSAYS 
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Table A2.1. Specific activity of MAO-N variants with α-MBA. 
 
Table A2.2. Specific activity of MAO-N variants with THIQ. 
MAO-N variant 
Total Protein in the 
assay (mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,191 0,005 
MAO-N D9 0,005 0,31 0,01 
MAO-N D11 0,005 0,016 0,001 
MAO-N D12 (A) 0,005 1,16 0,02 
MAO-N D12 (B) 0,0013 1,66 0,01 
MAO-N D12 (C) 0,0025 1,97 0,03 
MAO-N D12 (D) 0,005 1,46 0,09 
MAO-N D12 (E) 0,002 0,90 0,01 
MAO-N D12 (F) 0,002 0,564 - 
MAO-N D12 (G) 0,005 1,663 - 
MAO-N D12 (H) 0,005 2,25 0,01 
 
 
 
 
 
 
MAO-N variant 
Total protein in the 
assay (mg) 
Specific activity  
(U/mg of protein) 
Associated error  
(U/mg of protein) 
MAO-N D5 0,005 0,106 0,000 
MAO-N D9 0,005 1,73 0,05 
MAO-N D11 0,005 0,053 0,006 
MAO-N D12 (A) 0,005 0,43 0,05 
MAO-N D12 (B) 0,0013 0,68 0,02 
MAO-N D12 (C) 0,0025 0,52 0,02 
MAO-N D12 (D) 0,005 0,47 0,06 
MAO-N D12 (E) 0,002 0,369 0,008 
MAO-N D12 (F) 0,002 0,31 0,04 
MAO-N D12 (G) 0,005 0,29 0,01 
MAO-N D12 (H) 0,005 0,77 0,06 
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Table A2.3. Specific activity of MAO-N variants with 1-MTQ. 
MAO-N variant 
Total Protein in the 
assay(mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,007 0,000 
MAO-N D9 0,0025 2,11 0,03 
MAO-N D11 0,005 0,146 0,005 
MAO-N D12 (A) 0,005 0,145 0,009 
MAO-N D12 (B) 0,0013 0,044 0,001 
MAO-N D12 (C) 0,0025 0,026 0,001 
MAO-N D12 (D) 0,005 0,04 0,01 
MAO-N D12 (E) 0,002 0,026 0,000 
MAO-N D12 (G) 0,005 0,046 0,000 
MAO-N D12 (H) 0,005 0,37 0,03 
 
Table A2.4. Specific activity of MAO-N variants with 3-MTQ. 
MAO-N variant 
Total Protein in the 
assay (mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 - - 
MAO-N D9 0,0025 0,0054 0,0000 
MAO-N D11 0,0025 0,0025 0,0000 
MAO-N D12 (A) 0,005 0,012 0,001 
MAO-N D12 (B) 0,0013 0,0061 0,0000 
MAO-N D12 (C) 0,0025 0,0233 0,0009 
MAO-N D12 (D) 0,005 0,0120 0,0007 
MAO-N D12 (E) 0,002 - - 
MAO-N D12 (F) 0,002 0,0056 0,0000 
MAO-N D12 (G) 0,005 0,026 0,002 
MAO-N D12 (H) 0,005 0,031 0,001 
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Table A2.5. Specific activity of MAO-N variants with 4-MTQ. 
MAO-N variant 
Total Protein in the 
assay(mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,007 0,002 
MAO-N D9 0,0025 0,0040 0,0001 
MAO-N D11 0,0025 0,0019 0,0007 
MAO-N D12 (A) 0,005 0,061 0,001 
MAO-N D12 (B) 0,0013 0,088 0,009 
MAO-N D12 (C) 0,0025 0,1084 - 
MAO-N D12 (D) 0,005 0,0566 0,0009 
MAO-N D12 (E) 0,002 0,04 0,01 
MAO-N D12 (F) 0,002 0,015 0,003 
MAO-N D12 (G) 0,005 0,098 0,001 
MAO-N D12 (H) 0,005 0,1238 - 
 
Table A2.6. Specific activity of MAO-N variants with 5-MTQ. 
MAO-N variant 
Total Protein in the 
assay(mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,25 0,04 
MAO-N D9 0,0025 1,32 0,02 
MAO-N D11 0,0025 0,0223 0,0009 
MAO-N D12 (A) 0,005 1,20 0,05 
MAO-N D12 (B) 0,0013 1,64 0,03 
MAO-N D12 (C) 0,0025 1,24 0,09 
MAO-N D12 (D) 0,005 1,74 0,09 
MAO-N D12 (G) 0,005 1,31 0,03 
MAO-N D12 (H) 0,005 2,04 0,06 
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Table A2.7. Specific activity of MAO-N variants with 6-MTQ. 
MAO-N variant 
Total Protein in the 
assay(mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,029 0,001 
MAO-N D9 0,0025 0,72 0,02 
MAO-N D11 0,0025 0,2619 0,0006 
MAO-N D12 (A) 0,005 0,185 0,003 
MAO-N D12 (B) 0,0013 0,258 0,003 
MAO-N D12 (C) 0,0025 0,40 0,01 
MAO-N D12 (D) 0,005 0,490 0,004 
MAO-N D12 (G) 0,005 0,44 0,01 
MAO-N D12 (H) 0,005 0,396 0,005 
 
Table A2.8. Specific activity of MAO-N variants with 7-MTQ. 
MAO-N variant 
Total Protein in the 
assay(mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 - - 
MAO-N D9 0,005 - - 
MAO-N D11 0,005 - - 
MAO-N D12 (A) 0,005 0,0005 0,0001 
MAO-N D12 (B) 0,0013 0,0002 0,0000 
MAO-N D12 (C) 0,0025 0,0051 0,0002 
MAO-N D12 (D) 0,005 0,0015 0,0001 
MAO-N D12 (E) 0,002 - - 
MAO-N D12 (G) 0,005 0,0269 0,0003 
MAO-N D12 (H) 0,005 0,0023 0,0004 
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Table A2.9. Specific activity of MAO-N variants with 8-MTQ. 
MAO-N variant 
Total Protein in the 
assay (mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 0,0303 0,0005 
MAO-N D9 0,0025 1,915 0,017 
MAO-N D11 0,0025 0,61 0,03 
MAO-N D12 (A) 0,005 0,218 0,008 
MAO-N D12 (B) 0,0013 0,2480 0,0008 
MAO-N D12 (C) 0,0025 0,248 0,002 
MAO-N D12 (D) 0,005 0,24 0,03 
MAO-N D12 (G) 0,005 0,21 0,01 
MAO-N D12 (H) 0,005 0,44 0,01 
Table A2.10. Specific activity of MAO-N variants with DMTHIQ. 
MAO-N variant 
Total Protein in the 
assay (mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 - - 
MAO-N D9 0,0025 0,0038 0,0001 
MAO-N D11 0,0025 0,0006 0,0002 
MAO-N D12 (A) 0,005 0,0006 0,0002 
MAO-N D12 (B) 0,0013 - - 
MAO-N D12 (C) 0,0025 0,0039 0,0003 
MAO-N D12 (D) 0,005 0,0012 0,0004 
MAO-N D12 (G) 0,005 0,0054 0,0002 
MAO-N D12 (H) 0,005 0,0016 0,0002 
Table A2.11. Specific activity of MAO-N variants with 1-M-DMTHIQ. 
MAO-N variant 
Total Protein in the 
assay (mg) 
Specific activity 
(U/mg of protein) 
Associated error 
(U/mg of protein) 
MAO-N D5 0,005 - - 
MAO-N D9 0,005 0,0036 0,0004 
MAO-N D11 0,005 0,0017 0,0001 
MAO-N D12 (A) 0,005 0,0000 0,0004 
MAO-N D12 (B) 0,0013 - - 
MAO-N D12 (C) 0,0025 0,0024 0,0008 
MAO-N D12 (D) 0,005 - - 
MAO-N D12 (G) 0,005 - - 
MAO-N D12 (H) 0,005 0,0005 0,0002 
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1.1.2.  ANNEX 3. RESPONSE FACTORS 
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Figure A3.1. Normal phase HPLC trace (CHIRAPACK® IC™ 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 95/5/0.1, 1 mL/min, 254 nm) of a 2.5 mM 
equimolar solution of tetrahydroisoquinoline (103a) and 3,4-dihydroisoquinoline (104a). 
 
 
Figure A3.2. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 90/10/0.1, 1 mL/min, 254 nm) of 5-MTQ (103a) 
(top) and 5-methyl-3,4dihydroisoquinoline (104e) (bottom) 10 mM standards for 
determination of the response factor. 
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Figure A3.3. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 90/10/0.1, 1 mL/min, 254 nm) of 6-MTQ (103b) 
(top) and 6-methyl-3,4dihydroisoquinoline (104b) (bottom) 10 mM standards for 
determination of the response factor. 
 
 
Figure A3.4. Normal phase HPLC trace (CHIRAPACK® OD-H 250 mm x 4.6 mm, 5 µm, 
eluent: hexane/isopropanol/diethylamine = 90/10/0.1, 1 mL/min, 254 nm) of 8-MTQ (103c) 
(top) and 8-methyl-3,4dihydroisoquinoline (104c) (bottom) 10 mM standards for 
determination of the response factor. 
 
  
 
ANNEX 4. NMR SPECTRA 
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Figure A4.1. 1H NMR spectrum of 5-methyl-3,4-dihydroisoquinoline 
 
Figure A4.2. 1H NMR spectrum of 6-methyl-3,4-dihydroisoquinoline 
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Figure A4.3. 1H NMR spectrum of 8-methyl-3,4-dihydroisoquinoline. The signals 
corresponding to its protons are identified in the figure in black. The markings in green 
identify the signals corresponding to an amine contamination due to only partial conversion. 
The remaining amine signals could not be unequivocally assigned. 
 
Figure A4.4 1H NMR spectrum of 6,7-dimethoxy-3,4-dihydroisoquinoline. The signals 
corresponding to its protons are identified in the figure in black. The markings in green 
identify the signals corresponding to an amine contamination due to only partial conversion. 
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Figure A4.5 1H NMR of the product from the cyanation of 3,4-dihydroisoquinoline. The 
signals corresponding to the protons of 1-cyano-6-methyltetrahydroisoquinoline are 
identified in the figure in black. Also, the signal corresponding to the H-1 proton of its imine 
analogue is identified in red. 
 
Figure A4.6 13C NMR of the product from the cyanation of 3,4-dihydroisoquinoline. The 
signals corresponding to the carbons of 1-cyanotetrahydroisoquinoline are identified in the 
figure in black. The markings identify the signals corresponding to the carbons of imine 
contamination - in red - due to only partial conversion. Remaining imine signals could not 
be unequivocally identified. 
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Figure A4.7 1H NMR of the product from the cyanation of  
6-methyl-3,4-dihydroisoquinoline. The signals corresponding to the protons of  
1-cyano-6-methyltetrahydroisoquinoline are identified in the figure in black. The markings 
identify the signals corresponding to the protons of both amine - in green – and imine – in 
red - contamination due to only partial conversion. Remaining amine and imine signals could 
not be unequivocally identified. 
 
Figure A4.8. 13C NMR of the product from the cyanation of  
6-methyl-3,4-dihydroisoquinoline. The signals corresponding to the carbons of  
1-cyano-6-methyltetrahydroisoquinoline are identified in the figure in black. The signals 
corresponding to the carbons of the amine and imine contaminations could not be 
unequivocally identified. 
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Figure A4.9 1H NMR of the product from the cyanation of  
8-methyl-3,4-dihydroisoquinoline. The signals corresponding to the protons of  
1-cyano-8-methyltetrahydroisoquinoline are identified in the figure in black. The markings 
identify the signals corresponding to the protons of both amine - in green – and imine – in 
red - contamination due to only partial conversion. Remaining amine and imine signals could 
not be unequivocally identified. 
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Figure A4.10 13C NMR of the product from the cyanation of  
8-methyl-3,4-dihydroisoquinoline. The signals corresponding to the carbons of  
1-cyano-8-methyltetrahydroisoquinoline are identified in the figure in black. The markings 
identify the signals corresponding to the carbons of both amine - in green – and imine – in 
red - contamination due to only partial conversion. Remaining amine and imine signals could 
not be unequivocally identified. 
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Figure A4.11 1H NMR of the product from the cyanation of  
6,7-dimethoxy-3,4-dihydroisoquinoline. The signals corresponding to the protons of 
1-cyano-6,7-dimethoxytetrahydroisoquinoline are identified in the figure in black. The 
markings identify the signals corresponding to the protons of both amine - in green – and 
imine – in red - contamination due to only partial conversion. Remaining amine and imine 
signals could not be unequivocally identified. 
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Figure A4.12 1H NMR of the product from the cyanation of  
6,7-dimethoxy-3,4-dihydroisoquinoline. The signals corresponding to the carbons of  
1-cyano-6,7-dimethoxytetrahydroisoquinoline are identified in the figure in black. The 
markings identify the signals corresponding to the carbons of imine contamination - in red - 
due to only partial conversion. Remaining imine signals could not be unequivocally 
identified. 
* Overlapping nitrile and imine signals. 
 
